SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant |X|
Filed by a party other than the Registrant |_|
Check the appropriate box:
|_| Preliminary proxy statement
|X| Definitive proxy statement
|_| Definitive additional materials
|_| Soliciting material pursuant to Rule 14a-11(c) or Rule 14a-12
HUMAN GENOME SCIENCES, INC.
(Name of Registrant as Specified in Its Charter)
HUMAN GENOME SCIENCES, INC.
(Name of Person(s) Filing Proxy Statement)
Payment of filing fee (Check the appropriate box):
|X| No fee required.
|_| Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-----------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-----------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:1
-----------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-----------------------------------------------------------------------
(5) Total fee paid:
|_| Fee paid previously with preliminary materials:
|_| Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing of which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the form or schedule and the date of its filing.
(1) Amount previously paid:
-----------------------------------------------------------------------
(2) Form, schedule or registration statement no.:
-----------------------------------------------------------------------
(3) Filing party:
-----------------------------------------------------------------------
(4) Date filed:
-----------------------------------------------------------------------
1 Set forth the amount on which the filing fee is calculated and state how it
was determined.
<PAGE>
HUMAN GENOME SCIENCES, INC.
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD MAY 14, 1997
The Annual Meeting of Stockholders of Human Genome Sciences, Inc. (the
"Company") will be held at the University of Maryland System, Shady Grove
Center, 9640 Gudelsky Drive, Rockville, Maryland 20850-3480 on Wednesday, May
14, 1997 at 9:00 a.m., local time, to consider and act upon the following
matters:
1. To elect 11 Directors.
2. To approve amendments to the 1994 Stock Option Plan.
3. To consider and act upon proposed amendments to the Certificate
of Incorporation to provide for the classification of the
Company's Board of Directors into three classes and certain
related matters.
4. To ratify the appointment by the Board of Directors of Ernst &
Young LLP as the Company's independent auditors for the 1997
fiscal year.
5. To transact such other business as may properly come before the
meeting or any adjournments thereof.
Stockholders of record at the close of business March 17, 1997 will be
entitled to vote at the meeting or any adjournments thereof. A list of the
stockholders entitled to vote at the meeting will be open to the examination of
any stockholder of the Company, for any purpose germane to the meeting, during
ordinary business hours at the offices of the Company for the ten-day period
prior to the meeting.
By Order of the Board of Directors,
ROBERT H. BENSON, SECRETARY
Rockville, Maryland
April 28, 1997
WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE,
AND SIGN THE ENCLOSED PROXY AND MAIL IT PROMPTLY IN THE ENCLOSED, SELF-ADDRESSED
ENVELOPE SO THAT YOUR SHARES ARE REPRESENTED. NO POSTAGE IS NEEDED IF THE PROXY
IS MAILED WITHIN THE UNITED STATES.
<PAGE>
HUMAN GENOME SCIENCES, INC.
9410 KEY WEST AVENUE
ROCKVILLE, MARYLAND 20850-3338
PROXY STATEMENT FOR THE
ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD MAY 14, 1997
This Proxy Statement is furnished in connection with the solicitation
of proxies by the Board of Directors of Human Genome Sciences, Inc. (the
"Company") for use at the Annual Meeting of Stockholders to be held on May 14,
1997 and at all adjournments of that meeting (the "Meeting"). All proxies will
be voted in accordance with the instructions contained in them. If no choice is
specified, the proxies will be voted in favor of the matters set forth in the
accompanying Notice of Meeting. Any proxy may be revoked by a stockholder at any
time before its exercise by delivery of written revocation to the Secretary of
the Company.
On March 17, 1997, the record date for the determination of
stockholders entitled to vote at the Meeting, there were outstanding and
entitled to vote an aggregate of 18,870,460 shares of common stock, $.01 par
value per share ("Common Stock"), of the Company. Only shareholders of Record as
of March 17, 1997 are entitled to vote at this Meeting. Each share is entitled
to one vote.
The Company's Annual Report for the fiscal year ended December 31, 1996
is being mailed to stockholders with the mailing of this Notice and Proxy
Statement beginning on or about April 24, 1997.
VOTES REQUIRED
A majority of the issued and outstanding shares of Common Stock
entitled to vote constitutes a quorum at the Meeting. The affirmative vote of
holders of the majority of shares of Common Stock which are present and entitled
to vote are required to approve Proposal 2. The affirmative vote of holders of
at least the majority of the shares of Common Stock which are entitled to vote
at the Meeting is required to approve Proposal 3. Therefore, failure to vote on
any of these proposals has the same effect as a negative vote. Accordingly, if
stockholders do not vote their shares for Proposals 2 and 3, either in person or
by proxy, such stockholders will have effectively voted against the Proposals.
If approved, Proposal 3 will become effective upon the filing of a Certificate
of Amendment to the Certificate of Incorporation of the Company with the
Secretary of State of Delaware, which is expected to follow shortly after the
approval, if at all, of Proposal 3.
Shares of Common Stock represented in person or by proxy at the Meeting
(including shares that abstain or do not vote with respect to one or more of the
matters presented at the Meeting) will be tabulated by the inspectors of
election appointed for the Meeting whose tabulation will determine whether or
not a quorum is present. Abstentions will be counted as shares that are present
and entitled to vote for purposes of determining the presence of a quorum with
respect to any matter, but will not be counted as votes in favor of such matter.
Accordingly, an abstention from voting on a matter by a stockholder present in
person or represented by proxy at the Meeting will have the same legal effect as
a vote "against" the matter. If a broker holding stock in "street name"
indicates on the proxy that it
<PAGE>
does not have discretionary authority as to certain shares to vote on a matter,
those shares will not be considered as present and entitled to vote with respect
to that matter. Accordingly, a "broker non- vote" on a matter will have no
effect on the voting on such matter.
Candidates for election as members of the Board of Directors who
receive the highest number of votes, up to the number of directors to be chosen,
shall stand elected, and an absolute majority of the votes cast is not a
prerequisite to the election of any candidate to the Board of Directors.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of March 17, 1997 (except as
otherwise footnoted below), certain information regarding the ownership of
shares of Common Stock of (i) each person known by the Company to be the
beneficial owner of more than five percent of the outstanding shares of Common
Stock; (ii) each of the directors and named executive officers of the Company;
and (iii) all executive officers and directors of the Company as a group.
<TABLE>
<CAPTION>
Name and Address of Beneficial Owner(1) Number of Shares Owned Percent Owned
- --------------------------------------- ---------------------- -------------
<S> <C> <C>
Reliance Financial Services Corporation 2,449,624(2) 13.0%
Park Avenue Plaza
New York, New York 10055
SmithKline Beecham Corporation 1,355,338(3) 7.2
One Franklin Plaza
Philadelphia, Pennsylvania 19101
Rho Management Trust III 1,012,915(4) 5.4
c/o Rho Management Company, Inc.
767 Fifth Avenue
New York, New York 10153
Executive Officers and Directors
William A. Haseltine, Ph.D. 1,062,887(5) 5.6
c/o Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Michael J. Antonaccio, Ph.D. 50,000(6) *
c/o Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Robert A. Armitage None *
c/o Vinson & Elkins L.L.P.
1455 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
</TABLE>
- 2 -
<PAGE>
Name and Address of Beneficial Owner Number of Shares Owned Percent Owned
- ------------------------------------ ---------------------- -------------
Susan Bateson-McKay None(7) *
c/o Human Genome Sciences
9410 Key West Avenue
Rockville, Maryland 20850
Robert H. Benson, Ph.D., J.D. 39,000(8) *
c/o Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 2085
Melvin D. Booth 50,000(9) *
c/o Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
James H. Cavanaugh, Ph.D. 338,081(10) 1.8
Twin Towers at Metro Park
379 Thornall Street
Edison, New Jersey 08837
Beverly Sills-Greenough 6,750(11) *
211 Central Park West, #4-F
New York, NY 10024
Robert Hormats 2,000(12) *
c/o Goldman Sachs & Co.
85 Broad Street
New York, New York 10128
Donald D. Johnston 75,000(13) *
18 Oyster Shell Lane
Hilton Head, SC 29926
Max Link, Ph.D. 2,250(14) *
Tobelhofstr, 30
8044 Zurich, Switzerland
Bradley G. Lorimier 135,000(15) *
c/o Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Arthur M. Mandell 20,000(16) *
c/o Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
- 3 -
<PAGE>
Name and Address of Beneficial Owner Number of Shares Owned Percent Owned
- ------------------------------------ ---------------------- -------------
Steven C. Mayer 20,000(17) *
c/o Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Craig A. Rosen, Ph.D. 182,401(18) *
c/o Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Joshua Ruch 1,220,681(19) 6.5
c/o Rho Management Co., Inc.
767 Fifth Avenue
New York, New York 10153
James Barnes Wyngaarden, M.D. 14,250(20) *
3322 Dent Place, NW
Washington, DC 20007
All executive officers and directors 3,218,300(21) 16.7
as a group (17 persons)
- ----------
* Percentage is less than 1% of the total number of outstanding shares of the
Company.
(1) Except as otherwise indicated, each party has sole voting and investment
power over the shares beneficially owned.
(2) Includes shares owned by Reliance Insurance Company and Reliance National
Insurance Company (U.K.) Ltd., which are directly or indirectly
wholly-owned subsidiaries of Reliance Financial Services Corporation, based
on a Form 4 filed by Reliance Financial Services Corporation as of November
1, 1996.
(3) Based on the Form 13-D filed by SmithKline Beecham on January 27, 1997.
(4) Rho Management Partners L.P. ("Rho") may be deemed the beneficial owner of
shares registered in the name of Rho Management Trust III, pursuant to an
investment advisory agreement that confers sole voting and investment
control over such shares to Rho. Shares indicated include 6,915 shares
subject to immediately exercisable warrants. See also footnote (19).
(5) Does not include 15,500 shares of Common Stock owned by Dr. Haseltine's
wife, as to which Dr. Haseltine disclaims beneficial ownership, and 500,000
shares of Common Stock issuable upon exercise of options held that are not
exercisable within 60 days.
- 4 -
<PAGE>
(6) Includes 50,000 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days. Does not include 55,000 shares of
Common Stock issuable upon exercise of options held that are not
exercisable within 60 days.
(7) Does not include 20,000 shares of Common Stock issuable upon exercise of
options held that are not exercisable within 60 days.
(8) Includes 37,000 shares of Common stock issuable upon exercise of options
that are exercisable within 60 days. Does not include 60,000 shares of
Common Stock issuable upon exercise of options held that are not
exercisable within 60 days.
(9) Includes 50,000 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days. Does not include 250,000 shares of
Common Stock issuable upon exercise of options that are not exercisable
within 60 days.
(10) Includes 256,167 shares of Common Stock owned by HealthCare Ventures III
L.P., ("HCV III") and HealthCare Ventures IV L.P., ("HCV IV"). Mr.
Cavanaugh is general partner of HealthCare Partners III L.P., ("HCP III")
and HealthCare Partners IV L.P., ("HCP IV"), the general partners of HCV
III and HCV IV, respectively.
(11) Includes 6,750 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days. Does not include 4,500 shares of
Common Stock issuable upon exercise of options that are not exercisable
within 60 days.
(12) Does not include 11,250 shares of Common Stock issuable upon exercise of
options that are not exercisable within 60 days.
(13) Includes 18,609 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days.
(14) Does not include 9,000 shares of Common Stock issuable upon exercise of
options held that are not exercisable within 60 days.
(15) Includes 124,500 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days. Does not include 40,000 shares of
Common Stock issuable upon exercise of options held that are not
exercisable within 60 days.
(16) Includes 20,000 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days. Does not include 130,000 shares of
Common Stock issuable upon exercise of options held that are not
exercisable within 60 days.
(17) Includes 20,000 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days. Does not include 130,000 shares of
Common Stock issuable upon exercise that are not exercisable within 60
days.
- 5 -
<PAGE>
(18) Includes 40,522 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days. Also includes 36,000 shares of Common
Stock held in trust for Dr. Rosen's minor children, as to which Dr. Rosen
disclaims beneficial ownership. Does not include 106,000 shares of Common
Stock issuable upon exercise of options that are not exercisable within 60
days.
(19) As chief executive officer and controlling stockholder of the general
partner of Rho Management Partners L.P. ("Rho"), the investment advisor to
Rho Management Trust III, Joshua Ruch may be deemed to share voting and
investment control with Rho over shares registered in the name of Rho
Management Trust III, and therefore be considered a beneficial owner of
such shares. Includes an additional 205,266 shares held directly or
indirectly by Joshua Ruch individually or for the account of family
members, and 2,500 held by a foundation of which Joshua Ruch serves as a
trustee. See also footnote (4).
(20) Includes 14,250 shares of Common Stock issuable upon exercise of options
that are exercisable within 60 days. Does not include 15,750 shares of
Common Stock issuable upon exercise of options that are not exercisable
within 60 days.
(21) Includes 388,546 shares of Common Stock issuable upon exercise of options
and warrants that are exercisable within 60 days. Does not include 881,500
shares issuable upon exercise of options that are not exercisable within 60
days.
- 6 -
<PAGE>
PROPOSAL 1 - ELECTION OF DIRECTORS
It is proposed to elect 11 directors of the Company. Each nominee is
currently a director of the Company. At the Meeting, the persons named in the
enclosed proxy will vote to elect the directors listed below, unless the proxy
is marked otherwise. Each of the nominees has indicated his or her willingness
to serve, if elected; however, if any nominee should be unable to serve, the
proxies may be voted for a substitute nominee designated by the Board of
Directors.
If the amendment to the Certificate of Incorporation to provide for a
Classified Board of Directors (see "PROPOSAL 3") is adopted, the Board of
Directors will be divided into three classes. This Meeting will be the first
election of directors after the amendment which created the Classified Board.
Accordingly, at the Meeting, three directors will be elected for a term expiring
at the Company's 1998 Annual Meeting, four directors for terms expiring at the
1999 Annual Meeting, and four directors for a term expiring at the 2000 Annual
Meeting and, in each case, until their successors are duly elected and
qualified. At each Annual Meeting after 1997, directors will be elected to
succeed those directors whose terms then expire, and each person so elected will
serve for a three-year term.
If the Amendment to the Certificate of Incorporation is not approved,
directors elected at the Meeting will serve one-year terms until the 1998 Annual
Meeting and until their successors are duly elected and qualified.
<TABLE>
<CAPTION>
DIRECTOR PRINCIPAL OCCUPATION AND BUSINESS
NOMINEE AGE SINCE EXPERIENCE DURING THE PAST FIVE YEARS
------- --- ----- -------------------------------------
NOMINEES FOR TERMS EXPIRING IN 2000
<S> <C> <C> <C>
William A. Haseltine, Ph.D. 52 1993 Chairman of the Board, Chief Executive Officer, and
member of the Executive Committee of the Company.
Consultant to the Company from December 1992 until May
1993. Member of the Faculty of Harvard Medical School
and the Dana Farber Cancer Institute from 1976 to May
1993. Member of the faculty of the Harvard School of
Public Health from 1977 to May 1993 and Chief of Human
Retrovirology at the Dana Farber Cancer Institute from
1988 to May 1993. A founder of several biotechnology
companies. A Scientific Advisor to HealthCare
Investment Corporation, LLP ("HIC") since 1987. Author
of approximately 250 scientific publications.
- 7 -
<PAGE>
DIRECTOR PRINCIPAL OCCUPATION AND BUSINESS
NOMINEE AGE SINCE EXPERIENCE DURING THE PAST FIVE YEARS
------- --- ----- -------------------------------------
Melvin D. Booth 52 1995 President, Chief Operating Officer, and member of the
Executive Committee of the Company. Melvin D. Booth
has been President, Chief Operating Officer and
director of the Company since July 1995. Prior to this
time, Mr. Booth was with Syntex Corporation and its
subsidiaries from 1975 to 1995. Mr. Booth was the
President of Syntex Laboratories, Inc. from 1993 to
1995 and served as a Vice President of Syntex
Corporation from 1992 to 1995. From 1992 to 1993 he
served as the President of Syntex Pharmaceuticals
Pacific. From 1991 to 1992 he served as an area Vice
President of Syntex, Inc. From 1986 to 1991 he served
as the President of Syntex, Inc., Canada. He has been
active in U.S. pharmaceutical industry organization
and is also a past Chairman of the Pharmaceutical
Manufacturers Association of Canada. Mr. Booth holds a
Certified Public Accountant Certificate.
Robert D. Hormats 54 1996 Vice Chairman of Goldman Sachs (International) since
1987. Served in various capacities with Goldman Sachs
(International) since 1982. Served as a Senior Staff
Member for International Economic Affairs on the
National Security Council from 1974 to 1977. Served as
Senior Deputy Assistant Secretary for Economic and
Business Affairs at the Department of State from 1977
to 1979, Ambassador and Deputy U.S. Trade
representative from 1979 to 1981 and Assistant
Secretary of State for Economic and Business Affairs
from 1981 to 1982. Appointed by President Clinton in
1993 to the Board of the Russian-American Enterprise
Fund (now the U.S. Russia Investment Fund).
Joshua Ruch 47 1992 Member of the Executive and Compensation Committees.
President and controlling stockholder of the general
partner of Rho Management Partners L.P. ("Rho"), which
serves as investment advisor to Rho Management Trust
III, a principal stockholder of the Company.
Affiliated with Rho in various capacities since 1981.
- 8 -
<PAGE>
DIRECTOR PRINCIPAL OCCUPATION AND BUSINESS
NOMINEE AGE SINCE EXPERIENCE DURING THE PAST FIVE YEARS
------- --- ----- -------------------------------------
NOMINEES FOR TERMS EXPIRING IN 1999
James H. Cavanaugh 60 1992 Member of the Executive Committee. President of
HealthCare Investment Corp. since 1989 and a general
partner of HCP III, the general partner of HCV III,
and HCP IV, the general partner of HCV IV, and a
general partner of HealthCare Partners I, L.P. ("HCP
I") and HealthCare Partners II, L.P. ("HCP II"), the
general partners of HealthCare Ventures I, L.P. ("HCV
I") and HealthCare Ventures II, L.P. ("HCV II"),
respectively. Served as President of SmithKline &
French Laboratories - U.S. from March 1985 to February
1989 and as President of SmithKline Clinical
Laboratories from 1981 to 1985. Serves as a director
of several healthcare and biotechnology companies,
including MedImmune, Inc., Procept, Inc., Magainin
Pharmaceuticals, Inc. and Schire Pharmaceuticals
Group, PLC. Served as a director of the Pharmaceutical
Manufacturers Association, Unihealth America and the
Proprietary Association.
Max Link, Ph.D. 56 1995 Max Link, Ph.D. has served a s a director of the
Company since May 1995. In addition, Dr. Link has held
a number of executive positions with pharmaceutical
and healthcare companies. Most recently, he served as
Chief Executive Officer of Corange Limited, from May
1993 until June 1994. Prior to joining Corange,
Limited, Dr. Link served in a number of positions
within Sandoz Pharma Ltd., including Chief Executive
Officer, from 1990 until April 1992, and Chairman,
from April 1992 until May 1993. Dr. Link currently
serves on the board of directors of Procept, Inc. and
Protein Design Labs, Inc. Dr. Link received his
doctorate in Economics from the University of St.
Gallen.
Craig A. Rosen, Ph.D. 39 1992 Senior Vice President of Research and Development and
Director of the Company. Employed by the Roche
Institute of Molecular Biology from 1987 to December
1992, serving as Chairman of the Department of Gene
Regulation from 1991 to December 1992 and in varying
positions in the Department of Molecular Oncology and
Virology from 1987 to 1991. Member of the board and
chairman of the scientific advisory council for the
American Foundation for Aids Research from 1990 to
1995. Author of approximately 100 publications and an
editorial board member of several scientific
publications.
- 9 -
<PAGE>
DIRECTOR PRINCIPAL OCCUPATION AND BUSINESS
NOMINEE AGE SINCE EXPERIENCE DURING THE PAST FIVE YEARS
------- --- ----- -------------------------------------
Beverly Sills Greenough 67 1993 Member of the Audit Committee. Chairman of the Lincoln
Center for the Performing Arts since 1994. Managing
Director of the Metropolitan Opera in New York, a
position held since 1991. President of the New York
City Opera Board from 1989 to 1990. Served as General
Director of the New York City Opera Company from 1979
to 1989. Serves on the Boards of Directors of American
Express Company, Inc. and Time Warner,
Inc.
NOMINEES FOR TERMS EXPIRING IN 1998
Robert A. Armitage 49 1995 Partner in the Washington office of Vinson & Elkins
since 1993. Prior to joining Vinson & Elkins, he was
employed by the Upjohn Company in Kalamazoo, Michigan,
where he served as Vice President, Corporate Patents
and Trademarks, from 1983 to 1993. He is a past
chairman of the Patent Committee of the Pharmaceutical
Research and Manufacturers of America, Intellectual
Property Committee of the National Association of
Manufacturers, Intellectual Property Law Section of
the State Bar of Michigan; a former member of the
board of directors of Intellectual Property Owners and
a past president of the American Intellectual Property
Law Association and Association of Corporate Patent
Counsel.
Donald D. Johnston 71 1992 Member of the Executive Committee and Chairman of the
Compensation and Audit Committees. Employed by
Johnson & Johnson from 1961 until his retirement in
1986, serving as a director and member of the
Executive Committee from 1975 until 1986. Since
retiring, has served as an independent consultant to
Johnson & Johnson and to HIC. Chairman of Osteotech,
Inc.
James B. Wyngaarden, M.D.. 72 1993 Professor of Medicine and Sr. Associate Dean,
International Programs, University of Pennsylvania
Medical Center. Foreign Secretary, National Academy of
Sciences and Institute of Medicine and Associate Vice
Chancellor for Health Affairs at Duke University 1990
to 1994. Served as Director of the National Institutes
of Health from 1982 to 1989 and as Associate Director
for Life Sciences, Office of Science and Technology
Policy, Executive Office of the President from 1989 to
1990. From 1990 to 1991, served as Director of Human
Genome Organization. Serves as Director of Hybridon
Inc. since 1990 and Director of Magainen
Pharmaceuticals, Inc. since 1996. Served as a director
of Marion Merrill Dow Pharmaceutical Co. from 1990 to
1995 Author of approximately 250 scientific
publications.
</TABLE>
- 10 -
<PAGE>
SmithKline Beecham has the right to designate a nominee pursuant to the
terms of the Series B Convertible Preferred Stock Purchase Agreement (the "SB
Stock Purchase Agreement") and has designated Robert A. Armitage as its nominee.
SmithKline Beecham's right to designate a nominee continues until the
termination for certain specified reasons as defined in the Collaboration
Agreement or the later of (i) expiration of the initial research term under the
Collaboration Agreement or (ii) the date on which SmithKline Beecham
beneficially owns less than 5% of the Company's Common Stock (on a fully diluted
basis). For a description of the Collaboration Agreement, see "EXECUTIVE
COMPENSATION AND OTHER MATTERS--Certain Relationships and Related Transactions."
BOARD AND COMMITTEE MEETINGS
The Board of Directors held a total of four meetings during 1996. Dr.
Link was unable to attend two meetings.
The EXECUTIVE COMMITTEE was established to act on most matters during
the intervals between Board meetings. It has all the authority of the Board in
overseeing the business and affairs of the Company, except those powers that by
law cannot be delegated by the Board of Directors. The Executive Committee held
nine committee meetings during the 1996 fiscal year and currently consists of 5
directors: Drs. Haseltine and Cavanaugh and Messrs. Booth, Johnston, and Ruch.
The AUDIT COMMITTEE provides the opportunity for direct contact between
the Company's independent accountants and the Board. The Audit Committee makes
recommendations concerning the engagement of independent public accountants,
reviews with the independent public accountants the plans and results of the
audit engagement, and reviews the adequacy of the Company's internal accounting
controls. The Audit Committee, which currently consists of Mr. Johnston, as
Chairman, Mrs. Sills- Greenough, and Mr. Hormats held two meetings during the
1996 fiscal year.
The COMPENSATION COMMITTEE determines all compensation paid or awarded
to the Company's executive officers and senior officers (those with the rank of
vice president or above) and administers the Company's 1993 Incentive and
Non-Qualified Stock Option Plan and the 1994 Stock Option Plan (the "Plans"),
for which all employees and certain non-employees are eligible. The Compensation
Committee held eleven meetings during the 1996 fiscal year. The current members
of the Compensation Committee are Dr. Cavanaugh and Messrs. Ruch, and Johnston,
as Chairman.
The NOMINATING COMMITTEE consists of three directors: Drs. Haseltine
and Cavanaugh, and Mr. Johnston. The committee held two meetings during the 1996
fiscal year. The committee is responsible for proposing a slate of directors for
election by the shareholders at each annual meeting and proposing candidates to
fill any vacancies on the Board. The committee will consider candidates proposed
by shareholders for Board membership.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF THE NOMINATED
DIRECTORS.
PROPOSAL 2 - APPROVAL OF AMENDMENTS TO THE 1994 STOCK OPTION PLAN
On November 6, 1996 and January 21, 1997, the Board of Directors
approved amendments to the 1994 Stock Option Plan of Human Genome Sciences, Inc.
(as amended the "1994 Plan"), contingent upon approval by the stockholders at
the Meeting. The amendments increased the number of shares available
- 11 -
<PAGE>
for issuance under the 1994 Plan from 2,450,000 to 3,450,000 and provides for
automatic grants for non- employee directors. The 1994 Plan, prior to the
Amendment being submitted to the Stockholders hereby, prohibited grants of stock
options to members of the Stock Option Committee. This provision was included in
the 1994 Plan to meet the requirements of the Rule 16b-3 under the Securities
Exchange Act of 1934 as then in effect. As a result of an amendment to the
Securities Exchange Act of 1934, this restriction is no longer required. As of
March 17, 1997, 2,191,945 shares are subject to outstanding options issued and
106,705 options are available for grant (prior to the increase pursuant to the
Amendments). In addition, the Company maintains a 1993 Stock Option Plan, under
which 224,554 shares are subject to outstanding options issued and 59,134
options are available for grant. The purpose of the 1994 Plan, as amended, is to
enable the Company to attract, retain, and motivate the best available
individuals to serve as officers and employees of the Company and as members of
its Board of Directors.
The 1994 Plan, as amended, provides for the issuance of options
covering up to 3,450,000 shares of Common Stock, subject to appropriate
adjustments in the event of stock splits, stock dividends, and similar dilutive
events. Options may be granted under the 1994 Plan to all employees,
non-employee directors, independent contractors, and consultants of the Company
in the discretion of the Compensation Committee. As of March 28, 1997 there were
approximately 290 employees of the Company and 7 others eligible for such
grants.
Options granted may be either "incentive stock options" (as defined in
Section 422 of the Internal Revenue Code (the "Code")) or nonqualified stock
options. The exercise price of each option is determined by the Compensation
Committee at the time of the grant, provided that the exercise price of options
may not be less than the fair market value of the company's Common Stock on the
date of the grant.
The term of each option and the increments in which it is exercisable
are determined by the Compensation Committee, provided that no option may be
exercised (i) more than ten years of after the date of the grant, (ii) more than
three months after termination of an optionee's employment or other relationship
with the Company, or (iii) more than 12 months after an optionee's death or
disability. In addition, if an optionee owns more that 10% of the total voting
power of all classes of the Company's stock at the time the individual is
granted an incentive stock option, the exercise price per share cannot be less
than 110% of the fair market value on the date of the grant, and the term of the
incentive stock option cannot exceed five years from the date of the grant. The
Compensation Committee may provide that certain options will become exercisable
in increments based primarily or exclusively on the attainment of certain
performance goals. No option may be granted under the 1994 Plan more than ten
years after the date of the adoption of the 1994 Plan. The options are
non-transferable during the life of the option holder.
The 1994 Plan, as amended, provides for automatic grants of options to
purchase 10,000 shares of Common Stock on the date that each non-employee
director is first elected or appointed as a director and an automatic grant of
an option to purchase 2,000 shares of Common Stock to each non-employee director
on the date immediately following the Annual Meeting of Stockholders, commencing
on the day immediately following the date of the annual meeting of stockholders
for the company's fiscal year ending December 31, 1996. The exercise price for
each share subject to a Director Option shall be equal to the fair market value
of the Common Stock on the date of grant. Initial director options shall become
exercisable in five equal annual installments commencing one year from the date
of the option is granted and annual automatic grants will become exercisable in
full on the first anniversary of the date of grant.
- 12 -
<PAGE>
Options will expire the earlier of 10 years after the date of grant or 90 days
after the termination of the director's association with the Company.
Upon the occurrence of certain events, including the acquisition by
another corporation or person of shares of Common Stock representing more than
80% of the voting power of the Common Stock or a sale of substantially all the
property of the Company, the options granted under the 1994 Plan will become
fully exercisable for a period of time determined by the Company and will
terminate if not exercised within that period of time, unless separate provision
is made by the successor for their continuance.
The Company intends that the 1994 Plan qualify as a plan described in
Rule 16b-3 ("Rule 16b-3") of the Securities Exchange Act of 1934 (the "Exchange
Act"). Grants of options under the 1994 Plan will therefore be exempt from the
short-swing profit rules of Section 16(b) of the Exchange Act. The 1994 Plan may
be amended by the Board of Directors, consistent with Rule 16b-3, and the 1994
Plan specifically authorizes the Board of Directors to make any amendment deemed
necessary or advisable to ensure that incentive stock options and nonqualified
stock options continue to be treated as such, respectively, under all applicable
laws.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE APPROVAL OF THE
AMENDMENTS TO THE 1994 STOCK OPTION PLAN.
PROPOSAL 3 - CLASSIFICATION OF THE BOARD OF DIRECTORS AND RELATED
PROPOSAL
The Board of Directors has approved a resolution amending the Company's
Certificate of Incorporation to provide for a classified Board (the "Classified
Board") and to establish procedures for filling vacancies on the Board. The text
of the proposed amendment is attached to this Proxy Statement as Exhibit A. The
statements made in this Proxy Statement with respect to these amendments should
be read in conjunction with and are qualified in their entirety by reference to
Exhibit A.
Proposal 3 would, if adopted, operate to divide the Board into three
separate classes of directors, as nearly equal in number as possible, to serve a
three year term and until their successors are duly elected and qualified with
each class being elected at different annual stockholder meetings. Following the
effectiveness of Proposal 3, Class I directors will consist of four directors
who will serve for an initial term of three years, Class II directors will
consist of four directors who will serve for an initial term of two years, and
Class III directors will consist of three directors who will serve for an
initial term of one year. For an identification of these nominees see "PROPOSAL
1 - ELECTION OF DIRECTORS". At each annual meeting after 1997, directors will be
elected to succeed those whose terms then expire and each newly elected director
will serve for a three-year term. Proposal 3 would replace the present system of
electing all of the directors annually for one-year terms.
The effect of a Classified Board of Directors may otherwise be
circumvented by increasing or decreasing the size of the Board. At present,
vacancies in the Board of Directors, including vacancies resulting from an
increase in the number of directors, are required to be filled by a majority
vote of the remaining members of the Board, although less than a quorum, and
each person so elected serves as a director until a successor is elected by the
stockholders. Additionally, the size of the Board may be increased or decreased
at any time by the affirmative vote of holders representing a majority of the
Company's outstanding voting stock, except that the term of an incumbent
director cannot be shortened.
- 13 -
<PAGE>
Proposal 3 provides that the size of the Board may be fixed solely by action of
the Board itself, and that any vacancies in the Board of Directors can only be
filled by a majority vote of the remaining directors then in office, even though
less than a quorum, and each person so elected would serve until the annual
meeting of stockholders at which the class of directors for which he or she has
been chosen is elected. If the number of directors constituting the Board is
increased or decreased, the resulting number of directors will be apportioned
among the three classes so as to make all classes as nearly equal in number as
possible, except that the term of any incumbent director may not be shortened.
In addition, under the applicable provisions of the Delaware General Corporation
Law ("GCL"), as a result of the establishment of a Classified Board, directors
may only be removed for cause.
Adoption of Proposal 3 may have the effect of making it more difficult
for stockholders to remove the existing management of the Company and may,
therefore, discourage potentially unfriendly bids for shares of the Company. The
amendment may also impede assumption of the management of the Company by any
other person or entity which, through a takeover bid or otherwise, might obtain
a substantial number of shares of Common Stock. Proposal 3 is not being
recommended in response to any past problems regarding Board of Director
continuity or any specific effort of which the Board of Directors is aware to
accumulate the Company's stock or to acquire control of the Company, but rather
in recognition that such activities might occur in the future. In considering
Proposal 3, stockholders should consider and review the "REASONS FOR PROPOSAL 3"
and "POSSIBLE ANTI-TAKEOVER EFFECTS OF THE PROPOSAL 3".
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE CLASSIFICATION OF THE
BOARD OF DIRECTORS AND FOR THE ADOPTION OF PROPOSAL 3.
REASONS FOR PROPOSAL 3
The Board of Directors believes that Proposal 3 will enhance the
ability of the Company to carry out long-range plans and goals for the Company's
benefit and the benefit of its stockholders. Proposal 3 will promote these long
range plans and goals since, if adopted, it would establish a Classified Board,
creating directorships for longer terms which expire at different intervals.
Although the Company has not experienced difficulties in the past in maintaining
continuity of operations and management, the Board of Directors believes that a
Classified Board will assist the Company in maintaining this continuity into the
future. These provisions should increase the likelihood of continuity and
stability in the composition of the Board of Directors and, at the same time,
reduce the possibility that a third party could effect or threaten to effect a
sudden or surprise change in majority control of the Board of Directors without
the support of the incumbent Board. The Board of Directors does not believe that
the Company has had any problems in the past with respect to continuity in
leadership and policy.
A Classified Board would also extend the time it would take for a
hostile stockholder to obtain control of the Company's Board of Directors,
thereby limiting such abusive takeover tactics as two tiered tender offers.
Assuming each class of directors is equal in size, even a majority stockholder
could not obtain control of the Board until the second annual stockholders
meeting after it acquired a majority of the voting stock. During this time, the
Board of Directors would have a better opportunity to negotiate with any such
majority stockholder to obtain more favorable price and terms in any merger or
tender offer. In addition, Proposal 3 will eliminate the ability of the
stockholders to dismiss the entire Board of Directors
- 14 -
<PAGE>
and to increase or decrease the size of the Board, and will, therefore, further
promote continuity of operations and management.
POSSIBLE ANTI-TAKEOVER EFFECTS OF PROPOSAL 3.
Proposal 3 is intended to encourage persons seeking to acquire control
of the Company to initiate such an acquisition through arm's length negotiations
with the Company's Board of Directors. The Board of Directors believe that the
adoption of Proposal 3 will enable the Board of Directors to evaluate the
proposal and study alternative proposals in the absence of the coercive
atmosphere that might otherwise prevail and without the imminent threat of
removal. This ability to evaluate and negotiate will help ensure that the best
price is obtained in any acquisition transaction that may ultimately be
consummated.
Proposal 3 cannot, and is not intended to, prevent a purchase of all or
a majority of the equity securities of the Company nor is it intended to deter
bids or other efforts to acquire such securities. Rather, the Board of Directors
believes that Proposal 3 will encourage third parties which may seek to acquire
control of the Company to initiate such an acquisition through negotiations
directly with the Board of Directors. Therefore, the Board believes that it will
be in a better position to protect the interests of all of the stockholders if
Proposal 3 is approved. In addition, the stockholders of the Company will have a
more meaningful opportunity to evaluate such action.
Adoption of Proposal 3 may deter certain mergers, tender offers, proxy
contests or other future takeover attempts which holders of some or even a
majority of the outstanding stock believe to be in their best interests, and may
make removal of management more difficult even if such removal would be
beneficial in the judgment of many of the stockholders. Not all takeovers or
changes in control of the Board of Directors that are proposed and effected
without prior consultation and negotiation with the incumbent Board are
necessarily detrimental to the Company and its stockholders. However, the Board
believes that the benefits of seeking to protect its ability to negotiate with
the proponent of an unfriendly or unsolicited proposal to acquire or restructure
the Company outweigh the disadvantages of discouraging such proposals.
Although Proposal 3 is intended to encourage persons seeking to acquire
control of the Company to initiate such an acquisition through arm's length
negotiations with the Board the overall effect of these provisions may be to
discourage a third party from making a tender offer for a portion or all of the
Company's securities, hostile or otherwise (including an offer at a substantial
premium over the then prevailing market value of the Company's Common Stock), or
otherwise attempting to obtain a substantial portion of the Common Stock of the
Company in order to commence a proxy contest or engage in other takeover-related
action, even though some or a majority of the Company's stockholders might
believe such actions to be beneficial. If third parties are discouraged from
making offers for all or a substantial portion of the Company's Common Stock,
the effect may be to dampen demand for, or speculation in, the Company's Common
Stock and therefore negatively impact the price of the Common Stock.
To the extent that any third party potential acquirors are deterred by
Proposal 3, such provisions may serve to benefit incumbent management by making
it more difficult to remove management, even when the only reason for the
proposed change of control or the stockholder action may be the unsatisfactory
performance of the present directors. In addition, since Proposal 3 is, in part,
designed to discourage accumulating large blocks of the Company's voting
securities by purchasers whose objective is
- 15 -
<PAGE>
to gain control of the Company, their adoption could tend to reduce the
temporary fluctuation in the market price of such voting stock that frequently
results from such accumulations or attempted accumulations. Accordingly,
stockholders could be deprived of certain opportunities to sell their shares at
a higher market price.
RELATIONSHIP OF PROPOSAL 3 TO OTHER PROVISIONS
Existing provisions of the Delaware GCL and the Company's Certificate
of Incorporation may be deemed to discourage unsolicited takeover proposals
regardless of the adoption or rejection of the Proposals. Although the Company's
current Certificate of Incorporation does not contain provisions intended by the
Company to have, or to the knowledge of the Board of Directors having, an
anti-takeover effect, it currently authorizes the issuance of 50,000,000 shares
of Common Stock and 1,000,000 shares of Preferred Stock. The Board has the
authority to fix by resolution the designations, powers, preferences, rights,
qualifications, limitations or restrictions on the shares of Preferred Stock.
This authorized and available Common Stock and Preferred Stock could (within the
limits imposed by applicable law and the rules of the NASDAQ National Market) be
issued by the Company and used to discourage a change in control of the Company.
For example, the Company could privately place shares with purchasers who might
side with the Board of Directors in opposing a hostile takeover. Additionally,
the Board could designate a series of Preferred Stock to be issued in connection
with a rights plan. In addition, the Company's By-laws currently restrict the
calling of a special meeting to the Board of Directors, the President or the
Secretary at the request of shareholders of a majority of the voting stock. The
provision could make it more difficult for a party seeking to acquire control to
call a meeting for the election of directors or to take other desired corporate
action.
Once a Classified Board is established, the Delaware GCL prohibits
stockholders from removing members of a Classified Board without cause before
the expiration of their respective terms unless the Certificate of Incorporation
specifies otherwise. The Delaware GCL contains a number of other provisions
which are designed to strengthen the position of incumbent management in
connection with a takeover attempt. For example, Delaware law provides that a
corporation has the general power, exercisable by its board of directors, to
accept, reject, respond to or take no action in respect of an actual or proposed
acquisition, divestiture, tender offer, takeover or other fundamental change.
The case law of Delaware has developed special standards for deciding whether to
uphold or advocate the actions of incumbent management in the context of
takeover proposals.
The Company is also subject to Section 203 of the Delaware GCL, which
provides that a person who acquires fifteen percent (15%) or more of the
outstanding voting stock of a Delaware corporation becomes an "interested
stockholder". Section 203 prohibits a corporation from engaging in mergers or
certain other "business combinations" with an interested stockholder for a
period of three (3) years, unless (i) prior to the date the stockholder becomes
an interested stockholder, the board of directors approves either the business
combination or the transaction which results in the stockholder becoming an
interested stockholder; or (ii) the interested stockholder is able to acquire
ownership of at least eight-five percent (85%) of the outstanding voting stock
of the corporation (excluding shares owned by directors of the corporation who
are also officers and shares owned by certain employee stock plans) in the same
transaction by which the stockholder became an interested stockholder; or (iii)
the interested stockholder obtains control of the board of directors, which then
approves a business combination which is authorized by a vote of the holders of
two-thirds of the outstanding voting stock not held by the interested
stockholder.
- 16 -
<PAGE>
The definition of interested stockholder does not include persons whose
ownership of voting stock exceeds the fifteen percent (15%) threshold as a
result of action taken by the corporation unless that person thereafter acquires
additional shares.
A "business combination" is defined broadly in the Delaware GCL to
include any merger or consolidation with the interested stockholder, any merger
or consolidation caused by the interested stockholder in which the surviving
corporation will not be subject to Delaware law, or the sale, lease, exchange,
mortgage, pledge, transfer or other disposition to the interested stockholder of
any assets of the corporation having a market value equal to or greater than ten
percent (10%) of the aggregate market value of the assets of the corporation.
"Business combination" is also defined to include transfers of stock of the
corporation or a subsidiary to the interested stockholder (except for transfers
in conversion, exchange or pro rata distribution which do not increase the
interested stockholder's proportionate ownership of a class or series), or any
receipt by the interested stockholder (except proportionately as a stockholder)
of any loans, advances, guaranties, pledges or financial benefits.
PROPOSAL 4 - RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS
The Board of Directors is seeking ratification of the appointment of
Ernst & Young, LLP as its independent auditors for 1997. If a majority of
stockholders voting at the Meeting should not approve the selection of Ernst &
Young, LLP, the selection of independent auditors may be reconsidered by the
Board of Directors.
Ernst & Young, LLP is currently the Company's independent auditor. A
representative of Ernst & Young, LLP is expected to attend the Meeting and
respond to appropriate questions from stockholders.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR RATIFICATION OF THE
APPOINTMENT OF ERNST & YOUNG, LLP.
- 17 -
<PAGE>
EXECUTIVE COMPENSATION AND OTHER MATTERS
COMPENSATION OF DIRECTORS
In 1996, each director who was not an employee of the Company, a
consultant to the company, or associated with a collaborator of the Company was
eligible to receive a director's fee of $25,000 per year. Other directors
received no compensation for their services to the Company as directors. Each
non-employee director is also entitled to receive (i) an automatic grant of
options to purchase 10,000 shares of Common Stock on the date that each
non-employee director is first elected or appointed as a director and (ii) an
annual automatic grant of an option to purchase 2,000 shares of Common Stock.
See "PROPOSAL 2-APPROVAL OF AMENDMENTS TO THE 1994 STOCK OPTION PLAN". All
directors are reimbursed for expenses incurred in connection with attending
meetings of the Board of Directors.
In September 1992, the Company entered into a consulting agreement with
Donald D. Johnston, a director of the Company, for an initial term of one year.
This agreement was renewed for additional one year terms in September 1993,
1994, 1995 and 1996. Pursuant to the agreement, Mr. Johnston received a
consulting fee of $50,000 in the year ended August 31, 1996. Compensation for
the year ending August 31, 1997 will be $1 in addition to the standard directors
fee of $25,000. In connection with entering into the September 1992 agreement,
the Company sold 56,391 shares of restricted Common Stock to Mr. Johnston at a
purchase price of $.01 per share. All of the shares are subject to rights of
first refusal on sale (at a price of $.19 per share less than the price to be
paid in the proposed sale.)
In August, 1996 the Company granted Mr. Hormats options to purchase
11,250 shares of Common Stock at $32.25 per share. The options vest and become
exercisable in equal annual installments over a five-year period.
- 18 -
<PAGE>
EXECUTIVE COMPENSATION
<TABLE>
<CAPTION>
SUMMARY COMPENSATION TABLE
ANNUAL COMPENSATION LONG TERM COMPENSATION
------------------------------------------------ ---------------------------------------------------
AWARDS
OTHER RESTRICTED
ANNUAL STOCK ALL OTHER
SALARY(1) BONUS COMPENSATION(2) AWARD(S)(3) OPTIONS(4) COMPENSATION
NAME AND PRINCIPAL POSITION YEAR ($) ($) ($) ($) (#) ($)
- --------------------------- ----- ---------- ---------- ----------------- ------------- ------------- ----------------------
<S> <C> <C> <C> <C> <C>
William A. Haseltine, Ph.D. 1996 330,000 150,000 68,637(5)
Chief Executive Officer 1995 300,000 120,000 75,040(5)
1994 250,000 75,000 163,808(6)
Melvin D. Booth 1996 300,000 125,000
President and 1995 132,692 60,000 506,913(7) 300,000
Chief Operating Officer
Craig A. Rosen, Ph.D. 1996 252,600 100,000 45,000
Sr. Vice President 1995 235,000 70,000 50,000
1994 200,000 60,000 35,000
Bradley G. Lorimier 1996 245,000 100,000
Sr. Vice President (8) 1995 234,808 63,000
1994 177,404 60,000 139,336(9) 200,000
Michael J. Antonaccio, Ph.D. 1996 200,000 60,000
Vice President 1995 190,000 42,000
1994 125,308 40,000 119,310(10) 100,000
</TABLE>
- ----------
(1) Includes amounts earned but deferred at the election of the executive, such
as salary deferrals under the Company's 401(k) Plan established under
Section 401(k) of the Code.
(2) As permitted by rules promulgated by the Securities and Exchange
Commission, no amounts are shown with respect to certain perquisites (such
as car and housing allowances), where such amounts do not exceed the lesser
of (i) 10% of the sum of the salary and bonus of the Executive Officer, or
(ii) $50,000.
(3) No dividends were paid on stock or restricted stock for the fiscal years
ended December 31, 1994, 1995 and 1996.
(4) The Company has awarded no Stock Appreciation Rights.
(5) These amounts include $51,285 and $58,650 in imputed interest for 1996 and
1995 respectively, on an interest-free loan to Dr. Haseltine.(See --Loans
to Executive Officers).
(6) This amount includes a $93,000 housing allowance and $41,893 in imputed
interest on an interest-free loan to Dr. Haseltine (See --Loans to
Executive Officers).
- 19 -
<PAGE>
(7) On July 17, 1995, Mr. Booth joined the Company as President, Chief
Operating Officer. As an incentive for him to take the position, he was
given a $60,000 sign-on payment. Additionally, the Company paid $423,725
related to relocation costs.
(8) On February 13, 1997, the Company entered into a Retirement Agreement with
Mr. Lorimier (See --Employment Agreements).
(9) On March 14, 1994, Bradley Lorimier joined the Company as Senior Vice
President, Business Development. As an incentive for him to take the
position, he was given a $25,000 sign-on payment. Additionally, the Company
paid $114,336 in relocation costs.
(10) On April 15, 1994, Michael J. Antonaccio, Ph.D. joined the Company as Vice
President, Strategic Drug Development. As an incentive for him to take the
position, he was given a $15,000 sign-on payment. Additionally, the Company
paid $104,310 in relocation costs.
- 20 -
<PAGE>
OPTIONS GRANTED IN 1996
<TABLE>
<CAPTION>
Individual Grants
- --------------------------------------------------------------------------------- Potential realizable value at
Percent of total Exercise assumed annual rates of stock
options granted price per price appreciation for option
Options to all employees share Expiration term(1)
Name (#) in fiscal year ($) date --------------------------------
5% ($) 10% ($)
- -------------------------- --------- ---------------- ------------ ------------ -------------- -------------
<S> <C> <C> <C> <C> <C> <C>
William A. Haseltine, Ph.D. None
Melvin D. Booth None
Craig A. Rosen, Ph.D. 45,000 6% $38.25 Dec. 23, 2006 1,082,485 2,743,229
Bradley G. Lorimier None
Michael J. Antonaccio,Ph.D. 15,000 2% $37.00 Dec. 11, 2006 349,037 884,527
</TABLE>
- ----------
(1) The assumed annual rates of stock price appreciation of 5% and 10% are
required by the Securities and Exchange Commission to be used for
illustration purposes and are not intended to forecast possible future
appreciation, if any, of the Company's stock price.
<TABLE>
<CAPTION>
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND OPTION VALUES AT END OF FISCAL YEAR
NUMBER OF VALUE OF UNEXERCISED
UNEXERCISED OPTIONS IN-THE-MONEY OPTIONS
AT FISCAL YEAR-END AT FISCAL YEAR-END
SHARES (EXERCISABLE/ (EXERCISABLE/
ACQUIRED ON VALUE UNEXERCISABLE) UNEXERCISABLE)
NAME EXERCISE (#) REALIZED ($) (#) (#)
- ---------------------------------- --------------- ---------------- -------------------- ------------------------
<S> <C> <C> <C> <C>
William A. Haseltine, Ph.D. None None None None
Melvin D. Booth None None 50,000/250,000 812,500/4,062,500
Craig A. Rosen, Ph.D. 25,000 $938,750 40,522/106,000 1,127,967/1,018,250
Bradley G. Lorimier 35,500 $542,000 124,500/40,000 2,925,750/940,000
Michael J. Antonaccio, Ph.D. 10,000 $219,875 50,000/55,000 1,068,750/911,250
</TABLE>
- 21 -
<PAGE>
EMPLOYMENT AGREEMENTS
In February 1997, the Company entered in an employment agreement with
Dr. Haseltine that superseded his May 1993 employment agreement. The employment
agreement is for an initial term expiring in February 2000 and will
automatically extend for additional one-year periods unless terminated by either
party four months prior to the end of the applicable term. The employment
agreement provides that Dr. Haseltine is entitled to an annual base salary of
$350,000, and an annual bonus as determined by the Board of Directors and a car
allowance of $10,200 per year. The Company may terminate the employment
agreement without cause, and upon such termination, Dr. Haseltine will be
entitled to severance equal to his base salary for a period of 24 months. The
Company sold to Dr. Haseltine 661,160 shares of restricted Common Stock on May
18, 1993 at a purchase price of $.20 per share. The shares of Common Stock sold
to Dr. Haseltine vest in equal annual installments over a four-year period that
commenced on May 11, 1993. Unvested shares may be repurchased by the Company at
cost if Dr. Haseltine is terminated for cause or if Dr. Haseltine voluntarily
terminates his employment. All of the shares are subject to rights of first
refusal by the Company on sale (at a price per share equal to $1.13 less than
the price of the proposed sale).
In June 1995, the Company entered into an employment agreement with Mr.
Booth in which he agreed to serve as President and Chief Operating Officer of
the Company. The Company may terminate the agreement at any time and upon
termination without cause, Mr. Booth will be entitled to receive base salary
until the earlier of (i) eighteen months after termination of employment, or
(ii) until Mr. Booth commences other regular, full-time employment. The
agreement provides that Mr. Booth is entitled to an annual base salary, as
determined by the Board of Directors ($325,000 as of January 1, 1997), an annual
bonus of up to 35% of base salary, and a car allowance of $9,000 per year. The
Company paid Mr. Booth a sign-on payment of $60,000. The Company paid Mr. Booth
relocation costs of $423,725 in connection with his relocation to Maryland.
In October 1992, the Company entered into an employment agreement with
Dr. Rosen in which Dr. Rosen agreed to serve as Senior Vice President, Research
and Development of the Company. The employment agreement was for an initial term
ending in October 1995 and has been and will be automatically extended for
additional one-year periods unless terminated by either party prior to the end
of the applicable term. Dr. Rosen is entitled to an annual base salary, as
determined by the Board of Directors ($275,000 as of January 1, 1997), an annual
bonus of between 10% and 20% of his base salary, and a car allowance of $4,800
per year. The Company may terminate the employment agreement without cause, and
upon such termination, Dr. Rosen will be entitled to receive three months' base
salary. In April 1993, pursuant to the agreement, the Company sold to Dr. Rosen
140,977 shares of restricted Common Stock at a purchase price of $.01 per share.
All of the shares are subject to rights of first refusal by the Company on sale
(at a price per share equal to $.19 less than the price of the proposed sale).
In March 1994, the Company entered into an employment agreement with
Mr. Lorimier in which he agreed to serve as Senior Vice President, Business
Development of the Company. The employment agreement was for a term ending March
1997. The employment agreement provided that Mr. Lorimier was entitled to an
annual base salary, as determined by the Board of Directors ($250,000 as of
January 1, 1997), and an annual bonus, based on his performance, of between
$50,000 and $100,000. On February 13, 1997, the Company entered into a
Retirement Agreement with Mr.
- 22 -
<PAGE>
Lormier. Pursuant to the Retirement Agreement, Mr. Lormier, i) will retire
effective June 30, 1997, ii) has resigned as a director, iii) will be entitled
to payment of a pro rata bonus based on performance between January 1, 1997 and
his retirement date and iv) will be retained as a part-time consultant for a one
year period for compensation of $50,000 for such year. The Retirement Agreement
provides for the acceleration of the vesting of 40,000 unvested shares subject
to an option granted to Mr. Lormier on March 21, 1994 at an exercise price of
$17.50 and further provides that the option shall be exercisable through the
date which is 90 days following the expiration of the consulting period.
In March 1994, Dr. Antonaccio agreed to serve as Vice
President-Strategic Drug Development of the Company for an annual base salary,
as determined by the Board of Directors ($215,000 as of January 1, 1997).
LOANS TO EXECUTIVE OFFICERS
In November 1993, the Board of Directors authorized the extension of an
interest-free loan to Dr. Haseltine, in an amount up to $1,000,000, to enable
Dr. Haseltine to pay certain tax liabilities relating to his purchase of Common
Stock in May 1993. The loan was made on December 29, 1993 and was evidenced by a
promissory note dated March 4, 1994 in the amount of $872,845, replacing a
promissory note dated December 29, 1993. The loan was increased to $891,488 on
December 16, 1994. The loan was secured initially by 114,472 shares of issued
and outstanding Common Stock of the Company, whose market value at the time the
Common Stock was pledged was equal to 200% of the principal sum of the loan (the
"Collateral") and is now secured by 64,252 shares of Common Stock. The loan is
repayable in full (i) twenty business days after demand for repayment has been
made, (ii) twenty business days after Dr. Haseltine's employment has been
voluntarily terminated by Dr. Haseltine or terminated for cause by the Company,
(iii) on the date Dr. Haseltine defaults on the note, or (iv) December 29, 2003,
whichever occurs first. Dr. Haseltine is required to prepay the loan in full, or
in some instances, in part, if he sells any of the Collateral or Company
terminates his employment as a result of his death or disability or for any
reason other than for cause.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION IN COMPENSATION
DECISIONS
COMPENSATION COMMITTEE. From January to June 1996, the Compensation
Committee consisted of James Cavanaugh, William W. Crouse, Joshua Ruch and
Donald D. Johnston as Chairman. In June 1996, William W. Crouse resigned as
director of the Company.
INSIDER PARTICIPATION. Mr. Cavanaugh is a general partner of the
general partners of HCV III and HCV IV. HCV III and HCV IV are stockholders of
the Company and are deemed to hold 1.4% of the outstanding shares of Common
Stock of the Company. Rho Management Trust III, a principal stockholder of the
Company, is an affiliate of the prinicipal limited parnter of HCV IV. Mr. Ruch
is President and controlling stockholder of Rho Management Partners L.P. which
serves as investment advisor to Rho Management Trust III. See "SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT" and "--Certain
Relationship and Related Transactions."
- 23 -
<PAGE>
COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION
The Compensation Committee of the Board of Directors (the "Committee")
consists entirely of non-employee directors. The Committee determines all
compensation paid or awarded to the Company's executive officers and approves
the Company's overall compensation policies.
The Committee's goals are attract and retain an executive management
team that is capable of taking full advantage of the Company's opportunities,
and to provide incentives for outstanding performance. The Committee takes a
flexible and individualized approach, with a minimum of formal structure. In
arriving at an initial compensation offer to an individual, the Committee
considers determinants of the individual's market value, including experience,
education, accomplishments and reputation, as well as the level of
responsibility to be assumed, in relation to the market value of such
qualifications. When determining subsequent adjustments to an individuals
compensation package, the Committee also evaluates the importance to
shareholders of that person's continued service, based largely on recent
accomplishments. This is a judgment process, exercised by the Committee with the
advice of Company Management and a compensation consultant. The evaluation is
not tightly linked to performance against predetermined criteria, because such
systems interfere with creative opportunism.
The executive officers' compensation structure consists of: (i) base
salary, (ii) cash bonus and (iii) stock options.
BASE SALARY. Each individual's base salary is determined by the
Committee after considering a variety of factors that make up market value and
prospective value to the Company, including the knowledge, experience and
accomplishments of the individual, his level of responsibility, and the typical
compensation levels for individuals with similar credentials. The Committee may
change the salary of an individual on the basis of its judgment for any reason,
including the performance of the individual or the Company, changes in
responsibility, and changes in the market for executives with similar
credentials.
CASH BONUS. Bonus is for accomplishments during the past year. It is
determined by the Committee with advise from Company Management, based upon the
Committee's assessment of the individual's contributions during the year,
compared to, but not limited to, a list of goals previously approved by
Management and the Committee. In determining bonuses for the fiscal year ended
December 31, 1996, the Committee considered the establishment of seven new
collaborations with other companies based on HGS technology, continued progress
within collaborations previously established, progress in defining possible
therapeutic proteins for internal development or out-licensing, and further
additions to the Company's intellectual property and to its capability to
convert this to product development programs.
STOCK OPTIONS. Stock options are prospective incentives, aimed at
keeping and motivating key people by letting them share in the value they create
for stockholders. They are awarded at times deemed appropriate by the Committee
in amounts calculated to secure the full attention and best efforts of
executives on whose future performance the Company's success will depend.
Executive officers other than the C.E.O. (discussed below) received options on
210,000 shares in 1996, including one initial award.
- 24 -
<PAGE>
The Committee also believes significant equity participation is
important in attracting capable and entrepreneurial scientists and
administrators, so 580,616 shares were optioned to other managers and scientists
in 1996, pursuant to employee incentive plans approved by the Committee.
CHIEF EXECUTIVE OFFICER'S COMPENSATIONS. The Committee awarded Dr.
Haseltine a bonus of $150,000 for the fiscal year ended December 31, 1996. In
addition, effective January 1, 1997, Dr. Haseltine's base salary was increased
from $330,000 per year to $350,000 per year. The bonus and increase in salary
are based on the Committee's assessments of Dr. Haseltine's role in the
Company's performance in 1996, and on the continuing growth in his
responsibilities. Under Dr. Haseltine's leadership, the Company's capabilities
and opportunities were significantly enhanced by initiating collaborations which
multiply the potential for converting the Company's discoveries into products on
a timely basis. At the same time, the Company has negotiated rights to internal
development of selected products, and has made considerable progress in
evaluating their potential. Organizational development is keeping pace with the
expanding opportunities.
The final installment of Dr. Haseltine's 1,162,887 shares of founder's
stock vests during the first half of 1997. In view of Dr. Haseltine's importance
to the Company's accomplishments thus far and his demonstrated ability to
provide the scientific and business leadership the Company needs for the future,
the Committee decided to develop a stock option program for Dr. Haseltine which
would offer him the potential for exceptional equity growth, as attractive as
those he has earned in the Company's early years, if the stock price increases
enough to reward shareholders even more. With the advice of a leading
compensation consultant, the Committee estimated the option awards Dr. Haseltine
would receive over the next 5 years under a program typical of the Company's
peers, assuming continued top performance, and aggregated them into a single
grant on January 21, 1997, of options on 500,000 shares of Company common stock,
in lieu of anticipated annual grants during the coming 5 years. The terms are as
follows:
150,000 shares at market price ($41 as of January 21,
1997) for 5 years, vesting at the rate of
25% per year.
150,000 shares at $70 per share (71% over market price
as of January 21, 1997) for 7 years,
vesting at the rate of 20% per year.
200,000 shares at $100 per share (144% over market value
as of January 21, 1997) for 10 years,
vesting at the rate of 16 2/3% per year.
DIRECTORS COMPENSATION. The Committee has awarded stock options to
directors in the past only at the time of initial election to the Board. The
awards have typically been 11,250 shares, vesting at the rate of 2,250 share per
year. Reviewing past practices with our consultant, the Committee concluded that
the automatic grant of options to purchase shares of the Company at the time of
initial election or appointment as a director and each year thereafter, is
needed to enhance the attractiveness of service on the Board.
The Committee believes the amendment to the 1994 Plan developed by our
consultant, described in Proposal 2, will serve shareholder interests by helping
to attract top-cailber directors and focusing their attention on planning for
the Company's long-term success.
- 25 -
<PAGE>
COMPENSATION DEDUCTION LIMIT. The Committee has considered the $1
million limit on deductible executive compensation that is not performance
based, and believes all executive compensation expenses will be deductible by
the Company for the foreseeable future.
Compensation Committee
Donald D. Johnston, Chairman
Joshua Ruch
James H. Cavanaugh, Ph.D.
- 26 -
<PAGE>
PERFORMANCE GRAPH
The following graph compares the percentage change in the total
cumulative shareholder return on the Company's Common Stock since its initial
public stock offering completed on December 2, 1993 with the cumulative total
return on the Standard & Poor's Composite Index of 500 Stocks (the "S&P 500")
and the capital stocks of a peer group (the "Peer Group") of biotechnology
companies.* The comparison assumes $100 was invested on December 2, 1993 in the
Company's Common Stock and in each of the foregoing indices and assumes
reinvestment of dividends. The comparisons in this table are required by the SEC
and are not intended to forecast or be necessarily indicative of actual future
returns on the Company's Common Stock. In its 1994 Proxy Statement, the Company
compared the total shareholder returns for the Company's Common Stock to the S&P
500 and the Nasdaq Biotechnology Index ("NBI") for the 29 days following the
Company's initial public offering on December 2, 1993. The Company did not use
the NBI for comparison to the performance of the Company's Common Stock in 1994
because the NBI was not available for a portion of 1994. Moreover, the Company
believes that the Peer Group provides a better comparison for stock performance
in 1994 and for the future because the Peer Group is composed of companies more
representative of the Company's business.
[GRAPHIC OMITTED]
Indust
H&G S&P 500 Index
12/02/93 100.00 100.00 100.00
12/31/93 147.92 101.21 101.24
12/31/94 122.92 102.55 91.25
12/31/95 318.75 141.09 168.35
12/31/96 339.58 173.48 169.40
Notes:
1. The lines represent annual index levels derived from compounded daily
returns that include all dividends.
2. The indices are reweighted daily, using the market capitalization on
the previous trading day.
3. If the annual interval, based on the fiscal year-end, is not a trading
day, the preceding trading day is used.
- 27 -
<PAGE>
<TABLE>
<CAPTION>
The current composition of the Peer Group is presented below.
<S> <C> <C>
Advanced Tissue Science GeneMedicine Inc. Novavax Inc.
Alfacell Corp. Genetics Institute Inc. NPS Pharmaceuticals Inc.
AMBI Inc. Genta Incorporated Nyer Medical Group
American Biogenetic SCI Genzyme Corp. ONYX Pharmaceuticals Inc.
Amgen Inc. Genzyme Transgenics Corp. Oravax Inc.
Anergen Inc. Gilead Sciences Inc. Oxigene Inc.
Anika Therapeutics Inc. Gliatech Inc. Procept Inc.
Ansan Inc. Houghten Pharmaceuticals Protein Design Labs Inc.
Aphton Corp. Hybridon Inc. Qiagen NV
Ariad Pharmaceuticals IDEC Pharmaceuticals CP Repligen Corp.
AutoImmune Inc. IGI Inc. RIBI Immunochem Res Inc.
Aviron Imclone Systems Inc. Sangstat Medical Corp.
Biocryst Pharmaceuticals Immunex Corp. Senetek PLC ADR
Biogen Inc. Immune Response Crop. Seragen Inc.
Biomatrix Inc. Integra Lifesciences CP Serologicals Corp.
Biomira Inc. Interferon Sciences Inc. Somatix Therapy Corp.
Biotime Inc. La Jolla Pharmaceutical Somatogen Inc.
Cel-Sci Corp. Lifecore Biomedical Inc. Sparta Pharmaceuticals
Chrysalis Internat. Corp. LXR Biotechnology Inc. Sugen Inc.
Creative Biomolecules Magainin Pharmaceuticals Symbollon CP CL A
Cryolife Inc. Martek Biosciences Corp. Tageted Genetics CP
Curative Technologies Medarex Inc. Techne Corp.
Cypress Biosciences Inc. MedImmune Inc. Texas Biotechnology Corp.
Cytotherapeutics Inc. NABI Inc. Titan Pharmaceutical Inc.
Cytrx Corporation Neurex Corp. CL A Transkaryotic Therapies
Diacrin Inc. Neurobiological Tech. Vical Inc.
Embrex Inc. North Amer. Vaccine Vion Pharmaceuticals Inc.
Enzon Inc. Northfield Laboratories Viragen Inc.
Galagen Inc. Virus Research Institute
Zonagen Inc.
</TABLE>
THE FOREGOING GRAPH SHALL NOT BE DEEMED TO BE INCORPORATED BY REFERENCE INTO ANY
FILING OF THE COMPANY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
- 28 -
<PAGE>
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
AGREEMENTS WITH SMITHKLINE BEECHAM. In May 1993, the Company entered
into the SmithKline Beecham Collaboration Agreements pursuant to which
SmithKline Beecham was granted certain exclusive rights to develop and
commercialize therapeutic and diagnostic products within the "SB Field" (as
defined below) based on human genes discovered by the Company. Pursuant to the
SB Collaboration Agreements, SmithKline Beecham has paid to the Company an
aggregate of $125 million including $55.1 million which was allocated to the
purchase of an aggregate of 1,351,738 shares of Common Stock.
In June 1996, the SB Collaboration Agreements were substantially
amended (the "SB Amendment"). The SB Amendment allowed the Company and
SmithKline Beecham together to enter into collaboration agreements with
additional pharmaceutical companies ("New Collaboration Partners") in the SB
Field (other than diagnostics and animal healthcare in which SmithKline Beecham
has generally retained exclusive rights.) The "SB Field" is the field of human
and animal healthcare, other than gene therapy (excluding gene therapy
vaccines), antisense products and the use of genes for synthesizing drugs that
were known at the time the SB Collaboration Agreements were executed. In
addition, the SB Amendment provides that each of the Company and SmithKline
Beecham can independently designate potential therapeutic proteins for its
exclusive development and commercialization (e.g. marketing or outlicensing)
provided that it is the first among the Company, SmithKline Beecham and the New
Collaboration Partners to select the protein and certain research requirements
are met prior to such designation. In addition, the SB Amendment provides
procedures under which the Company and SmithKline Beecham may independently (i)
research, develop and commercialize antibody products directed against antigens
derived from the human genome database created by the Company and (ii) identify
and use novel molecular targets derived from the human genome database created
by the Company to discover and develop small molecule pharmaceutical products,
provided that the Company will not initiate screening of such targets for three
years from the effective date of the SB Amendment and will not use certain
targets subject to agreements with third parties, subject to certain other
restrictions.
The SB Amendment provides that SmithKline Beecham and the Company will
share equally in any license fees and product development milestone payments
paid under New Collaboration Partner Agreements, and that the Company will
receive all royalties and research support payments under such New Collaboration
Partner Agreements. The SB Collaboration Agreements provide for payments to the
Company of royalties on net sales of products based on the Company's patents or
technologies within the SB Field ("SB Products") sold by SmithKline Beecham (or
its licensees) and milestone payments in connection with the development of SB
Products. The Company has an option to co- promote SB Products sold by
SmithKline Beecham, on a country-by-country basis, in the United States, Canada,
Mexico and Europe (subject to certain limitations as to rights granted to Takeda
and other parties). If the Company develops and markets or outlicenses a product
in the SB Field pursuant to its rights under the agreements with SmithKline
Beecham, SmithKline Beecham will generally be entitled to royalties or to share
in milestone payments and license fees received by the Company from licensees
with respect to such products. The New Collaboration Partner Agreement with
Schering Corporation and Schering-Plough, Ltd. (collectively "Schering-Plough")
includes an option for Schering-Plough to co-develop and co-commercialize up to
two products in the SB Field to which the Company has exclusive development and
commercialization rights under the SB Collaboration Agreements. The SB
- 29 -
<PAGE>
Collaboration Agreements include an option for SmithKline Beecham to co-develop
and co- commercialize products in the SB Field to which the Company has
exclusive development and commercialization rights under the SB Collaboration
Agreements and for which Schering-Plough has not exercised its option to
co-develop and co-commercialize. SmithKline Beecham will also be entitled to
royalties on, and an option to co-promote products outside the SB Field sold by
the Company which are based on or incorporate patents or information developed
by SmithKline Beecham based on the Human Genome Technology of the Company.
The initial research term under the SB Collaboration Agreements
continues through June 2001. After expiration of the initial research term, the
Company will have all rights to the Company's Human Gene Technology, except that
SmithKline Beecham will retain rights to the Company's Human Gene Technology
pursuant to research plans meeting certain specified criteria submitted prior to
expiration of the initial term, Takeda will retain rights granted to it under a
license agreement prior to expiration of the initial research term and New
Collaboration Partners will retain rights granted to them under New
Collaborations Partner Agreements. SmithKline Beecham has the right to extend
the research term for up to five additional years by making certain payments,
which would extend the time for submitting research plans as to therapeutic
products other than antibody products and therapeutic protein products.
The Company also agreed to use its best efforts to elect a nominee
designated by SmithKline Beecham as a director of the Company. SmithKline
Beecham has named Robert A. Armitage to be nominated by the Board of Directors
to stand for election as Director. SmithKline Beecham is also entitled to a
right of first refusal to purchase new shares of Common Stock in any issuance of
equity securities by the Company, other than issuances of certain excluded
securities (all as defined in the Stock Purchase Agreement), in amounts which
would not enable it to exceed its percent ownership of the Company as of the
execution date of the Collaboration Agreement. SmithKline Beecham waived this
right of first refusal in connection with the Company's public offerings. These
rights continue until the expiration of the initial research term (as defined in
the Stock Purchase Agreement) or termination of the Collaboration Agreement
between the Company and SmithKline Beecham for certain reasons.
In July 1995, the Company entered into a collaboration agreement with
MedImmune with respect to the development of drugs based upon infectious agents
sequenced by the Company or TIGR or as to which the Company has licensed the
rights. The agreement provides that MedImmune will select, research, develop and
commercialize product candidates from the Company's information and patents
relating to bacteria. The Company will be entitled to share in the net profits
from the sale of any products covered by patent claims of the Company or joint
patent rights and to share in license fees from products covered by such claims.
The agreement is terminable by either party for a certain period after notice of
termination is given and includes certain provisions restricting the Company and
MedImmune from collaborating with others in the areas covered by the
collaboration agreement during the term. In November 1996, the Company entered
into a collaboration agreement with OraVax Merieux Co. in which MedImmune and
the Company granted an exclusive license for use of the Company's and
MedImmune's technology for certain vaccine development. Dr. Cavanaugh is a
Director and beneficial owner of shares of common stock of MedImmune, Inc.
The Company believes that all transactions between the Company and its
officers, directors, principal stockholders or affiliates thereof, including the
transactions with TIGR, in light of all of the circumstances of the
transactions, have been, and will in the future be, on terms no less favorable
to the Company than could be obtained from unaffiliated third parties.
- 30 -
<PAGE>
OTHER MATTERS
The Company's executive officers, directors, and ten percent beneficial
owners of Common Stock are required to file reports of ownership and change of
ownership with the Securities and Exchange Commission under the Exchange Act.
The Board of Directors knows of no other business that may come before
the Meeting. If any other business is properly presented at the Meeting, it is
the intention of the persons named in the accompanying proxy to vote, or
otherwise act, in accordance with their judgment on such matters.
Notwithstanding anything to the contrary set forth in any of the
Company's previous filings under the securities laws that might incorporate
future filings, the report of the Compensation Committee and the performance
graph included in this Proxy Statement shall not be incorporated by reference
into any such filing.
THE COMPANY WILL PROVIDE WITHOUT CHARGE A COPY OF THE COMPANY'S ANNUAL
REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 1996, INCLUDING
FINANCIAL STATEMENTS AND SCHEDULES, TO EACH OF THE COMPANY'S STOCKHOLDERS OF
RECORD ON MARCH 17, 1997, AND TO EACH BENEFICIAL OWNER OF STOCK ON THAT DATE,
UPON RECEIPT OF A WRITTEN REQUEST THEREFOR MAILED TO THE COMPANY'S OFFICES, 9410
KEY WEST AVENUE, ROCKVILLE, MARYLAND 20850- 3338, ATTENTION INVESTOR RELATIONS
OFFICE. IN THE EVENT THAT EXHIBITS TO SUCH FORM 10-K ARE REQUESTED, A FEE WILL
BE CHARGED FOR REPRODUCTION OF SUCH EXHIBITS. REQUESTS FROM BENEFICIAL OWNERS OF
COMMON STOCK MUST SET FORTH A GOOD FAITH REPRESENTATION AS TO SUCH OWNERSHIP.
SOLICITATION OF PROXIES
All costs of solicitation of proxies will be borne by the Company. In
addition to solicitation by mail, the Company's directors, officers, and regular
employees, without additional remuneration, may solicit proxies by telephone,
telegraph and personal interviews. Brokers, custodians, and fiduciaries will be
requested to forward proxy soliciting material to the beneficial owners of
Common Stock held in their names, and the Company will reimburse them for their
out-of-pocket expenses incurred in connection with the distribution of proxy
materials.
- 31 -
<PAGE>
PROPOSALS FOR THE 1998 ANNUAL MEETING
Proposals of stockholders intended to be presented at the 1997 Annual
Meeting of Stockholders must be received by the Company at its principal office
in Rockville, Maryland not later than December 19, 1997 for inclusion in the
proxy statement for that meeting.
By Order of the Board of Directors,
ROBERT H. BENSON, SECRETARY
April 28, 1997
THE BOARD OF DIRECTORS HOPES THAT YOU WILL ATTEND THE MEETING. WHETHER
OR NOT YOU PLAN TO ATTEND, PLEASE COMPLETE, DATE, SIGN, AND RETURN THE ENCLOSED
PROXY IN THE ACCOMPANYING ENVELOPE PROMPTLY. IF YOU ATTEND THE MEETING, YOU MAY
WITHDRAW YOUR PROXY AND VOTE YOUR OWN SHARES.
- 32 -
<PAGE>
EXHIBIT A
PROPOSAL 3
----------
The following shall be added as the second paragraph under Article V of
the Certificate of Incorporation:
"Terms of Directors. The number of Directors of the Corporation shall
be fixed by resolution duly adopted from time to time by the Board of Directors.
The Directors, shall be classified, with respect to the term for which they hold
office, into three classes, as nearly equal in number as possible. The initial
Class I Director shall serve for a term expiring at the annual meeting of
stockholders to be held in 2000, the initial Class II Directors shall serve for
a term expiring at the annual meeting of stockholders to be held in 1999, and
the initial Class III Directors shall serve for a term expiring at the annual
meeting of stockholders to be held in 1998. At each annual meeting of
stockholders, the successor or successors of the class of Directors whose term
expires at that meeting shall be elected by a plurality of the votes cast at
such meeting and shall hold office for a term expiring at the annual meeting of
stockholders held in the third year following the year of their election. The
Directors elected to each class shall hold office until their successors are
duly elected and qualified or until their earlier resignation or removal."
The following shall be added as the third paragraph under Article V of
the Certificate of Incorporation.
"Vacancies. Any and all vacancies in the Board of Directors, however
occurring, including, without limitation, by reason of an increase in size of
the Board of Directors, or the death, resignation, disqualification or removal
of a Director, shall be filled solely by the affirmative vote of a majority of
the remaining Directors then in office, even if less than a quorum of the Board
of Directors. Any Director appointed in accordance with the preceding sentence
shall hold office until the annual meeting of stockholders at which the class of
directors for which he or she has been chosen is elected and until such
Director's successor shall have been duly elected and qualified or until his or
her earlier resignation or removal. When the number of Directors is increased or
decreased, the Board of Directors shall determine the class or classes to which
the increased or decreased number of Directors shall be apportioned so as to
maintain each class as nearly equal in number as possible; provided, however,
that no decrease in the number of Directors shall shorten the term of any
incumbent Director.
- 33 -
<PAGE>
1994 STOCK OPTION PLAN OF HUMAN GENOME SCIENCES, INC.
(AS AMENDED)
I. GENERAL PROVISIONS
1.1 PURPOSES OF THE PLAN
Under this 1994 Stock Option Plan of Human Genome Sciences, Inc. (the
"Plan"), Human Genome Sciences, Inc. (the "Company") will grant options to
eligible employees, consultants, and other service providers to purchase shares
of the capital stock of the Company. The Plan is designed to enable the Company
to attract, retain, and motivate its employees and service providers by
providing for or increasing their proprietary interests in the Company. The
options issued pursuant to the Plan are intended to constitute either Incentive
Stock Options or Nonqualified Stock Options as determined by the Committee and
specified in the recipient's option agreement.
1.2 DEFINITIONS
(a) "Board" means the Board of Directors of Human Genome Sciences, Inc.
(b) "Code" means the Internal Revenue Code of 1986, as amended.
(c) "Committee" means the Executive Compensation Committee of the
Board, or such other committee as may be appointed by the Board for purposes of
administering all or a portion of this Plan.
(d) "Common Stock" means the common stock, par value $0.01 per share,
of Human Genome Sciences, Inc.
<PAGE>
(e) "Company" means Human Genome Sciences, Inc., a Delaware
corporation.
(f) "Date of Exercise" means the date the Optionee delivers to the
Secretary of the Company or his office the notice specified in Section
2.6(a)(i).
(g) "Date of Grant" means the date as of which the Committee awards an
Option to an Optionee, as specified in the minutes of the Committee.
(h) "Employee" means any regular full-time common law employee,
including any who are also officers or directors, of the Company or any
successor to such corporation or other business. Solely for purposes of
determining eligibility of persons to be recipients of Nonqualified Stock Option
grants, the term "Employee" shall also include independent contractors and
outside directors of and consultants to the Company.
(i) "Exchange Act" means the Securities Exchange Act of 1934, as
amended.
(j) "Exercise Price" means the value of the consideration required
under an Option Agreement to be provided in exchange for one share of Common
Stock.
(k) "Fair Market Value" of a share of Common Stock as of a given date
means (1) the closing price of a share of Common Stock on the principal exchange
on which Common Stock is then trading, if any, on the trading day before such
date, or, if no shares were traded on the trading day before such date, then on
the next preceding trading day during which a sale occurred; or (2) if such
stock is not traded on an exchange but is quoted on NASDAQ or a successor
quotation system, (A) the last sales price (if the stock is then listed as a
National Market Issue under the NASD National Market System) or (B) the mean
between the closing representative bid and asked prices (in all other cases) for
the stock on the trading day before such date as reported by NASDAQ or such
successor quotation system; or (C) if such stock is not publicly traded on an
exchange and not quoted on NASDAQ or a successor quotation system,
- 2 -
<PAGE>
the mean between the closing bid and asked prices for the stock on the trading
day before such date, as determined in good faith by the Committee; or (4) if
Common Stock is not publicly traded, the fair market value established by the
Committee acting in good faith.
(l) "Incentive Stock Option" means an Option that is an "incentive
stock option" within the meaning of Section 422 of the Code.
(m) "Nonqualified Stock Option" means an Option that does not qualify
as an incentive stock option under Section 422 of the Code.
(n) "Option" means a right to purchase Common Stock granted under the
Plan.
(o) "Option Agreement" means a written agreement executed by the
Optionee and the Company that contains the terms and conditions provided in
Article II and such additional terms and conditions, consistent with the Plan,
as the Committee may decide.
(p) "Optionee" means any Employee selected to receive Options pursuant
to Section 2.1 or, where the context requires, a person described in Section
2.4.
(q) "Plan" means the Company's 1994 Stock Option Plan as set forth
herein, as amended from time to time.
(r) "Rule 16b-3" means Rule 16b-3 promulgated under Section 16 of the
Exchange Act.
(s) "Termination of Employment" shall mean the time when the
employer-employee or other service-providing relationship between the Optionee
and the Company terminates for any reason, including death, disability, or
retirement. Notwithstanding the foregoing and unless otherwise provided in the
Option Agreement, "Termination of Employment" for purposes of Nonqualified Stock
Options shall not include instances in which the Company immediately
- 3 -
<PAGE>
rehires a common law employee as an independent contractor or an independent
contractor as an employee. The Committee, in its sole discretion, shall
determine all questions of whether particular terminations or leaves of absence
are Terminations of Employment.
1.3 SHARES OF COMMON STOCK SUBJECT TO THE PLAN
(a) Subject to the provisions of Sections 1.3(c) and 3.1 (pertaining to
corporate changes), the aggregate number of shares of Common Stock that may be
issued pursuant to Options may not exceed 3,450,000 shares.
(b) At the discretion of the Board or the Committee, the Common Stock
to be issued pursuant to Options under the Plan will be made available either
from authorized but unissued shares of Common Stock or from previously issued
shares of Common Stock reacquired by the Company, including shares purchased on
the open market.
(c) If any Option expires, is canceled, or terminates for any reason,
the shares of Common Stock available under such Option shall again be available
for the granting of Options to the extent consistent with Rule 16b-3.
1.4 ADMINISTRATION OF THE PLAN
(a) The Committee, which will administer the Plan, will consist of two
or more members of the Board who are appointed by the Board, who are
"non-employee directors" within the meaning of Rule 16b-3, and who are "outside
directors" for purposes of Section 162(m) of the Code.
- 4 -
<PAGE>
(b) Subject to the express provisions of the Plan, the Committee has
and may exercise such powers and authority of the Board as may be necessary or
appropriate for the Committee to carry out its functions as described in the
Plan.
(c) The Committee has the authority to interpret the Plan, to make all
other determinations necessary or advisable for the administration of the Plan,
and to prescribe, amend, and rescind reasonable rules and regulations relating
to the Plan. All Committee interpretations, determinations, and actions will be
final, conclusive, and binding upon all parties. The Committee shall take all
actions in connection with the administration of the Plan pursuant to a majority
vote or by the unanimous written consent of its members.
(d) No member of the Board, the Committee, or the agents thereof will
be liable for any action, inaction, or determination made in good faith with
respect to the Plan or any transaction arising under the Plan.
II. OPTION TERMS AND CONDITIONS
2.1 AUTHORITY TO GRANT OPTIONS
(a) The Committee shall, in its sole discretion, select the Employees
who receive Options and determine the terms of such Options, including the
number of shares of Common Stock subject to an Option, the schedule for
exercisability (including any requirements for satisfying performance criteria
with respect to the Company and/or the Optionee), the time and conditions for
expiration of the Option, and the form of payment due upon exercise. (In
determining the type of payment that may be used, the Committee shall consider
whether the acceptance of that form of payment will likely benefit the Company.)
The Committee may grant more than one Option to an Employee, provided the
Employee is eligible under the terms of the Plan at the time of each succeeding
grant. In its discretion, the Committee may condition the granting of Options
- 5 -
<PAGE>
upon the Employee's cancellation of all or part of a previously granted Option.
The Committee may set the Exercise Price of the Options without regard to any
existing Options.
(b) No more than 500,000 shares of Common Stock may be subject to
Options granted to a single Employee under this Plan within a one calendar year
period. If a portion of an Option is repriced, the number of shares subject to
that portion shall be counted against the foregoing individual limit. Canceled
options shall be counted against the limit for the period during which they were
granted.
(c) No Options shall be granted more than ten (10) years after the date
on which the Board adopts this Plan.
(d) Directors of the Company who are not employees of the Company
("Eligible Directors") will receive an option ("Director Option") to purchase
10,000 shares of Common Stock on the date that such person is first elected or
appointed a director ("Initial Director Option"). Commencing on the day
immediately following the date of the annual meeting of stockholders for the
Company's fiscal year ending December 31, 1996, each Eligible Director will
receive an automatic grant ("Automatic Grant") of a Director Option to purchase
2,000 shares of Common Stock on the day immediately following the date of each
annual meeting of stockholders, as long as such director is a member of the
Board of Directors. The exercise price for each shares subject to a Director
Option shall be equal to the fair market value of the Common Stock on the date
of grant. Initial Director Options shall become exercisable in five equal annual
installments commencing one year from the date the option is granted and
Automatic Grants will become exercisable in full on the first anniversary of the
date of grant or 90 days after the termination of the director's association
with the Company.
- 6 -
<PAGE>
2.2 OPTION AGREEMENT
The terms of each Option shall be contained in an Option Agreement,
signed by the Optionee, that includes such terms and conditions consistent with
the Plan and Rule 16b-3 as the Committee may in its discretion determine
necessary or advisable.
2.3 EXERCISE PRICE
The Committee shall determine the Exercise Price under each Option, but
the Exercise Price may not be less than 100 percent (100%) of the Fair Market
Value on the Date of Grant. If an Option intended to be an Incentive Stock
Option is granted to any Employee who, at the Date of Grant, owns Common Stock
possessing more than 10 percent (10%) of the total combined voting power of all
classes of the Company's stock (or the stock of any "subsidiary" or "parent" of
the Company as those terms are defined in Section 424 of the Code), the Exercise
Price shall be no less than 110 percent (110%) of the Fair Market Value on the
Date of Grant.
2.4 PERSON WHO MAY EXERCISE OPTIONS
During the lifetime of the Optionee, only the Optionee or his duly
appointed guardian or personal representative may exercise the Options. After
his death, any exercisable portion of an Option may, before such portion becomes
unexercisable under the Plan or the applicable Option Agreement, be exercised by
the personal representative of the Optionee or by any person empowered to do so
under the deceased Optionee's will or under the then applicable laws of descent
and distribution.
2.5 EXERCISABILITY
(a) Options granted pursuant to this Plan shall be exercisable at such
times and under such conditions as shall be determined by the Committee;
provided, however, that no portion of
- 7 -
<PAGE>
an Option shall be exercisable after the expiration of ten (10) years from its
Date of Grant and that no portion of an Incentive Stock Option granted to any
Employee who, at the Date of Grant, owns stock possessing more than 10 percent
(10%) of the total combined voting power for all classes of the Company's stock
(or the stock of any "subsidiary" or "parent" of the Company as those terms are
defined in Section 424 of the Code) shall be exercisable after the expiration of
five (5) years from the Date of Grant.
(b) Subject to the provision of Section 3.7 (relating to shareholder
approval), Options shall become exercisable at such times and in such manner as
the Option Agreement may provide; provided, however, that by a resolution
adopted after an Option Agreement is entered into, the Committee may, on such
terms and conditions as it determines appropriate, and subject to Section 3.7,
accelerate the time at which the Optionee may exercise any portion of an Option.
(c) No portion of an Option that is unexercisable by reason of
Termination of Employment shall thereafter become exercisable, unless the Option
Agreement provides otherwise.
(d) The Company will not issue fractional shares pursuant to the
exercise of an Option, but the Committee may, in its discretion, direct the
Company to make a cash payment instead of issuing fractional shares.
2.6 EXERCISE OF OPTIONS
(a) An Optionee shall exercise any portion of an Option by delivering
the notice described in Paragraph (1) below to the Secretary of the Company or
his office on or before the date such portion of the Option becomes
unexercisable under the applicable Option Agreement or the Plan and making
payment as provided in Paragraph (2) within three (3) business days after such
delivery:
- 8 -
<PAGE>
(1) A written notice of exercise, in a form complying with any
rules the Committee may issue, that is signed by the Optionee and that
specifies the number of shares of Common Stock underlying the portion
of the Option being exercised; and
(2) Full payment by cashier's or certified check of the Exercise
Price for the shares of Common Stock with respect to which the Option
is being exercised.
(b) The Optionee shall also deliver to the Committee such
representations and documents as the Committee, in its sole discretion, may
consider necessary or advisable in order to comply with applicable provisions of
the Securities Act of 1933 and any other Federal or state securities or other
laws or regulations. The Committee may, in its sole discretion, take whatever
additional actions it deems appropriate to so comply including, without
limitation, placing legends on certificates and issuing stop-transfer orders to
transfer agents and registrars.
(c) If someone other than the Employee exercises any portion of an
Option pursuant to Section 2.4, the Committee may request such proof as it may
consider necessary or appropriate of the right of such person to exercise the
Option.
(d) No adjustment will be made for a dividend or other right for which
the record date precedes the Date of Exercise, except as provided in Section
3.1(a).
2.7 TAX WITHHOLDING
The Optionee must deliver to the Company the payment by cashier's or
certified check to the Company of all amounts that the Company must withhold
under Federal, state, or local law in connection with the exercise of the Option
if the Company cannot, or decides not to, satisfy withholding obligations
through additional withholding on salary or wages. Payment of withholding
obligations is due at the same time as is payment of the Exercise Price.
- 9 -
<PAGE>
2.8 EXPIRATION OF OPTIONS
(a) No one may exercise an Option after the expiration of ten (10)
years from the Date of Grant or, if earlier and unless otherwise provided in an
Option Agreement for a Nonqualified Stock Option, the first to occur of the
following events:
(1) Except in the case of any Optionee who is disabled (within
the meaning of Section 22(e)(3) of the Code), the expiration of three
months from the date of the Optionee's Termination of Employment for
any reason other than the Optionee's death unless the Optionee dies
within that three-month period;
(2) In the case of an Optionee who is disabled (within the
meaning of Section 22(e)(3) of the Code), the expiration of one year
from the date of the Optionee's Termination of Employment for any
reason other than such Optionee's death unless the Optionee dies
within that one-year period; or
(3) The expiration of one year from the date of the Optionee's
death.
(b) Subject to the provisions of Section 2.8(a), the Committee may
provide in the terms of an Option Agreement that any portion of the Option,
whether then exercisable or not, expires immediately upon a Termination of
Employment or that any portion of the Option shall become exercisable in the
event of a Termination of Employment because of the Optionee's retirement,
death, or disability.
2.9 TRANSFER RESTRICTIONS
Unless otherwise approved in writing by the Committee, no one may sell,
assign, pledge, encumber, or otherwise transfer shares acquired upon exercise of
any Option until at least six months have elapsed from (but excluding) the Date
of Grant. (Solely for purposes of this
- 10 -
<PAGE>
Section, the Date of Grant occurs upon the later of the Date of Grant (as
defined in Section 1.2(g)) or the date as of which the shareholders of the
Company approve the Plan pursuant to Section 3.7.) The Committee, in its
absolute discretion, may impose such other restrictions on the transferability
of the shares purchasable upon the exercise of an Option as it deems
appropriate. The Option Agreement shall set forth any such other restriction,
and the certificates evidencing such shares may refer to such restrictions.
2.10 $100,000 LIMIT FOR INCENTIVE STOCK OPTIONS
No portion of an Option granted to an Optionee shall be treated as an
Incentive Stock Option to the extent such portion of an Option would cause the
aggregate Fair Market Value of all shares with respect to which Incentive Stock
Options are exercisable by such Optionee for the first time during any calendar
year to exceed $100,000. For purposes of determining whether an Incentive Stock
Option would cause such aggregate Fair Market Value to exceed the $100,000
limitation, all such Incentive Stock Options shall be taken into account in the
order granted and the Fair Market Value for each share under an option shall be
determined as of that option's date of grant. For purposes of this section,
Incentive Stock Options include all incentive stock options under all plans of
the Company that are "incentive stock option plans" within the meaning of
Section 422 of the Code.
2.11 NO EXERCISE OF OUT-OF-THE-MONEY OPTIONS
An Optionee may not exercise any portion of an Option while that
portion of the Option is out-of-the-money, i.e., while the exercise price for a
share of Common Stock underlying that portion of the Option exceeds the Fair
Market Value of a share of Common Stock.
- 11 -
<PAGE>
III. OTHER PROVISIONS
3.1 ADJUSTMENT PROVISIONS
(a) Subject to any required action by the Company (which shall be
promptly taken) or its shareholders, and subject to the provisions of the
Delaware General Corporation Law, if the outstanding Common Stock are increased
or decreased or changed into or exchanged for a different number or kind of
security by reason of any recapitalization, reclassification, stock split,
reverse stock split, combination of shares, exchange of shares, stock dividend,
or other distribution payable in capital stock, or other increase or decrease in
such Common Stock is effected without receipt of consideration by the Company
occurring after the Date of Grant of an Option, a proportionate and appropriate
adjustment shall be made in the number of shares of Common Stock underlying the
Option, so that the proportionate interest of the Optionee immediately following
such event shall, to the extent practicable, be the same as immediately before
such event. A commensurate change will be made in the maximum number and kind of
shares provided in Section 1.3(a) and 2.1(b). Any such adjustment in an Option
shall not change the total price with respect to shares of Common Stock
underlying the unexercised portion of the Option but shall include a
corresponding proportionate adjustment in the Option's Exercise Price.
(b) In addition to the adjustments covered under Section 3.1(a) above,
any Option grant may contain provisions to the effect that upon the occurrence
of certain events, including a change in control of the Company (as defined by
the Committee in the Optionee's Option Agreement), any outstanding Options not
theretofore exercisable or free from restrictions, as the case may be, shall
either immediately, or upon a further determination made by the Committee at the
time of the event, become fully exercisable or free from restrictions.
(c) The Committee will make adjustments and determinations under
Sections 3.1(a) and 3.1(b), and its determination will be final, binding, and
conclusive.
- 12 -
<PAGE>
(d) Upon the dissolution or liquidation of the Company, or upon a
reorganization, merger, or consolidation of the Company as a result of which the
outstanding securities of the class of securities then subject to the Options
are changed into or exchanged for cash or property or securities not of the
Company's issue, or any combination thereof, or upon a sale of substantially all
the property of the Company to, or the acquisition of shares of Common Stock
representing more than eighty percent (80%) of the voting power of the shares of
Common Stock then outstanding by, another corporation or person, the Options
shall terminate, unless provision be made in writing in connection with such
transaction for the assumption of Options theretofore granted under the Plan, or
the substitution for such options of any options covering the stock or
securities of a successor employer corporation, or a parent or subsidiary
thereof, with appropriate adjustments as to the number and kind of shares of
stock and prices, in which event the Options shall continue in the manner and
under the terms so provided. If an Option would otherwise terminate pursuant to
the foregoing sentence, the Optionee shall have the right, at such time before
the consummation of the transaction causing such termination as the Company
shall reasonably designate, to exercise the unexercised portions of the Option,
including the portions thereof that would, but for this subsection, not yet be
exercisable.
3.2 CONTINUATION OF EMPLOYMENT OR SERVICE
Nothing in the Plan or in any instrument executed pursuant to the Plan
will confer upon any Optionee any right to continue in the employ or service of
the Company or affect the right of the Company to terminate the employment or
service of any Optionee at any time with or without cause, subject to any
contrary terms in a written employment agreement or contract for services with
the Optionee.
3.3 COMPLIANCE WITH GOVERNMENT REGULATIONS
No shares of Common Stock will be issued pursuant to an Option until
all applicable requirements imposed by Federal and state securities and other
laws, rules, and regulations, and
- 13 -
<PAGE>
by any regulatory agencies having jurisdiction, and by any stock exchanges upon
which the Common Stock may be listed have been fully met. As a condition
precedent to the issuance of shares of Common Stock pursuant to an Option, the
Company may require the Optionee to take any reasonable action to comply with
such requirements.
3.4 PRIVILEGES OF STOCK OWNERSHIP
No Optionee and no beneficiary or other person claiming under or
through such Optionee will have any right, title, or interest in or to any
shares of Common Stock allocated or reserved under the Plan or subject to any
Option except as to such shares of Common Stock, if any, that have been issued
to such Optionee.
3.5 NONTRANSFERABILITY OF OPTIONS AND COMMON STOCK
Unless otherwise approved in writing by the Committee, an Option may
not be assigned, transferred, pledged, hypothecated, or disposed of in any way,
whether by operation of law or otherwise or through any legal or equitable
proceedings (including bankruptcy), to any person by the Optionee, except by
will or by operation of applicable laws of descent and distribution. Unless
otherwise approved in advance in writing by the Committee, the Optionee may not
sell, assign, pledge, encumber, or otherwise transfer shares of Common Stock
acquired upon exercise of an Option until at least six (6) months have elapsed
from (but excluding) the Date of Grant. The Committee, in its sole discretion,
may impose such other restrictions on the transferability of Options, as it
deems appropriate. The Option Agreement shall set forth any such other
restrictions, and the certificates evidencing such shares of Common Stock may
refer to such restrictions.
- 14 -
<PAGE>
3.6 AMENDMENT AND TERMINATION OF PLAN; AMENDMENT OF OPTION
(a) The Board will have the power, in its sole discretion, to amend,
suspend, or terminate the Plan at any time; provided, however, that the Board
may not amend the Plan without approval of the shareholders of the Company if
Rule 16b-3 requires such approval. The Board is specifically authorized to adopt
any amendment to this Plan deemed by the Board to be necessary or advisable to
ensure that the Incentive Stock Options or Nonqualified Stock Options available
under the Plan continue to be treated as such, respectively, under all
applicable laws.
(b) Except as otherwise provided by the applicable Option Agreement or
by Section 1.4, 3.1, or 3.8, the Committee may not, without the consent of an
Optionee, make modifications in the terms and conditions of an Option that
adversely affect the Optionee. No Incentive Stock Option may be modified,
extended, or renewed, without the consent of an Optionee, if such action would
cause it to cease to be an incentive stock option within the meaning of Section
422 of the Code.
(c) No amendment, suspension, or termination of the Plan will, without
the consent of the Optionee, alter, terminate, impair, or adversely affect any
right or obligations under any Option previously granted under the Plan.
3.7 APPROVAL OF PLAN BY STOCKHOLDERS
The Company will submit this Plan for the approval of the Company's
shareholders. The Committee may grant Options before such shareholder approval,
but the Optionee cannot exercise Options before the shareholders approve the
Plan. Moreover, if the shareholders do not approve the Plan within 12 months
after the Board's initial adoption of the Plan, all Options previously granted
under the Plan shall thereupon be canceled and become void. The Company shall
take such actions regarding the Plan as may be necessary to satisfy the
requirements of Rule 16b-3(b).
- 15 -
<PAGE>
3.8 CONFORMITY TO SECURITIES LAW
The Plan is intended to conform to the extent necessary with all
provisions of the Securities Act of 1933 and the Exchange Act and all
regulations and rules promulgated by the Securities and Exchange Commission
thereunder, including without limitation Rule 16b-3. Notwithstanding anything
herein to the contrary, the Committee shall administer the Plan, and Options
shall be granted and may be exercised, only in such a manner as to conform to
such laws, rules, and regulations. To the extent permitted by applicable law,
the Plan and Options granted hereunder shall be deemed amended to the extent
necessary to conform to such laws, rules, and regulations. To the extent any
provision of the Plan or action by the Committee fails to comply with Rule 16b-3
(as in effect with respect to the Plan on the date such action is taken), the
provision or action shall be deemed null and void, to the extent permitted by
law and deemed advisable by the Committee.
3.9 APPLICABLE LAW
This Plan shall be governed by and construed in accordance with the
laws of the State of Delaware.
IV. DURATION OF PLAN
Unless sooner terminated by the Board, the Plan will terminate on March
14, 2004.
- 16 -
<PAGE>
PLEASE DATE, SIGN AND MAIL YOUR
PROXY CARD BACK AS SOON AS POSSIBLE!
ANNUAL MEETING OF STOCKHOLDERS
HUMAN GENOME SCIENCES, INC.
MAY 14, 1997
<TABLE>
<CAPTION>
PLEASE DETACH AND MAIL IN THE ENVELOPE PROVIDED
- ------------------------------------------------------------------------------------------------------------------------------------
A [ ]PLEASE MARK YOUR
[ X ]VOTES AS IN THIS
[ ]EXAMPLE.
<S> <C>
FOR ALL NOMINEES WITHHOLD MANAGEMENT RECOMMENDS A VOTE FOR THE
AT RIGHT (EXCEPT AS AUTHORITY NOMINEES FOR DIRECTOR LISTED BELOW
MARKED TO THE TO VOTE FOR ALL
CONTRARY BELOW) NOMINEES LISTED
PROPOSAL 1 [ ] [ ] NOMINEES:
TO ELECT [ ] [ ] WILLIAM A. HASELTINE, Ph.D. ROBERT HORMATS
11 DIRECTORS. [ ] [ ] MELVIN D. BOOTH DONALD D. JOHNSTON
TO WITHHOLD AUTHORITY TO VOTE ON ANY CRAIG A. ROSEN, Ph.D. MAX LINK, Ph.D.
NOMINEE(S) WRITE EACH NOMINEE(S) ROBERT A. ARMITAGE JOSHUA RUCH
NAME(S) BELOW: JAMES H. CAVANAUGH, Ph.D JAMES BARNES WYNGAARDEN, M.D.
BEVERLY SILLS GREENOUGH
- ------------------------------------
MANAGEMENT RECOMMENDS A VOTE FOR PROPOSALS 2,3 AND 4.
- ------------------------------------
FOR AGAINST ABSTAIN
- ------------------------------------ PROPOSAL 2. TO APPROVE AMENDMENTS TO [ ] [ ] [ ]
THE COMPANY'S 1994 STOCK OPTION [ ] [ ] [ ]
PLAN. [ ] [ ] [ ]
PROPOSAL 3. TO CONSIDER AND ACT UPON
PROPOSED AMENDMENTS TO THE CERTIFI- [ ] [ ] [ ]
CATE OF INCORPORATION TO PROVIDE FOR [ ] [ ] [ ]
THE CLASSIFICATION OF THE COMPANY'S [ ] [ ] [ ]
BOARD OF DIRECTORS INTO THREE
CLASSES.
PROPOSAL 4. TO RATIFY THE SELECTION
OF ERNST & YOUNG, LLP AS THE [ ] [ ] [ ]
COMPANY'S INDEPENDENT AUDITORS FOR [ ] [ ] [ ]
THE FISCAL YEAR ENDING DECEMBER 31, [ ] [ ] [ ]
1997.
THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE
MANNER DIRECTED HEREIN BY THE STOCKHOLDER. IF NO SPECIFICATION
IS MADE, THIS PROXY WILL BE VOTED IN FAVOR OF PROPOSALS.
PLEASE VOTE, DATE AND PROMPTLY RETURN THIS PROXY IN THE
ENCLOSED RETURN ENVELOPE WHICH IS POSTAGE PREPAID IF MAILED
WITHIN THE UNITED STATES.
SIGNATURE(S)__________________________________________________________________________________ DATE_____________________________
NOTE: PLEASE SIGN EXACTLY AS NAME APPEARS HEREON. IF THE STOCK IS REGISTERED IN THE NAMES OF TWO OR MORE PERSONS, EACH SHOULD SIGN.
EXECUTORS, ADMINISTRATORS, TRUSTEES, GUARDIANS AND ATTORNEYS-IN-FACT SHOULD ADD THEIR TITLES. IF A SIGNATORY IS A CORPORATION,
PLEASE GIVE THE FULL CORPORATE NAME AND HAVE A DULY AUTHORIZED OFFICER SIGN STATING TITLE. IF A SIGNATORY IS A PARTNERSHIP, PLEASE
SIGN IN PARTNERSHIP NAME BY AUTHORIZED PERSON.
</TABLE>
HUMAN GENOME SCIENCES, INC.
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS FOR THE
ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 14, 1997
The undersigned hereby appoints WILLIAM A. HASELTINE, Ph.D. and ROBERT H.
BENSON, and each of them, as attorneys and proxies of the undersigned, with full
power of substitution, to vote all of the shares of common stock of Human Genome
Sciences, Inc. (the "Company") which the undersigned may be entitled to vote at
the Annual Meeting of Stockholders of the Company to be held at the University
of Maryland System, Shady Grove Center, 9640 Gudesky Drive, Rockville, Maryland
20850, on May 14, 1997 at 9:00 a.m., local time, and at any and all
continuations and adjournments thereof, with all powers that the undersigned
would possess if personally present, upon and in respect of the following
matters and in accordance with the following instructions, with discretionary
authority as to any and all other matters that may properly come before the
meeting.
UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR ALL
NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSALS 2, 3 AND 4, AS MORE SPECIFICALLY
DESCRIBED IN THE PROXY STATEMENT. A VOTE TO ABSTAIN WILL HAVE THE SAME LEGAL
EFFECT AS A VOTE "AGAINST" THE MATTER.
